샘플 요청 목록

 카트 문의
시장보고서
상품코드
1742726

세계의 세균 백신 시장

Bacterial Vaccines
발행일: | 리서치사: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 페이지 정보: 영문 490 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계의 세균 백신 시장은 2030년까지 358억 달러에 도달

2024년에 249억 달러로 추정되는 세계의 세균 백신 시장은 분석 기간인 2024-2030년에 CAGR 6.2%로 성장하며, 2030년에는 358억 달러에 달할 것으로 예측됩니다. 백일해(Pertussis/Whooping Cough) 백신은 이 리포트에서 분석한 부문의 하나이며, CAGR은 5.0%를 기록하며, 분석 기간 종료시에는 92억 달러에 달할 것으로 예측됩니다. 기타 백신 유형 분야의 성장률은 분석 기간 중 CAGR 4.5%로 추정됩니다.

미국 시장은 68억 달러로 추정, 중국은 CAGR 9.6%로 성장 예측

미국의 세균 백신 시장은 2024년에 68억 달러로 추정됩니다. 세계 2위의 경제대국인 중국은 2030년까지 72억 달러의 시장 규모에 달할 것으로 예측되며, 분석 기간인 2024-2030년의 CAGR은 9.6%입니다. 기타 주목할 만한 지역별 시장으로는 일본과 캐나다가 있으며, 분석 기간 중 CAGR은 각각 3.2%와 6.0%로 예측됩니다. 유럽에서는 독일이 CAGR 4.1%로 성장할 것으로 예측됩니다.

세계의 세균 백신 시장 - 주요 동향과 촉진요인 정리

왜 세균 백신이 감염병 대응, 항균제 내성 완화, 세계 보건 대비의 전략적 자산으로 재조명되고 있는가?

세계 보건 시스템이 항균제 내성(AMR) 증가, 백신으로 예방 가능한 질병의 부활, 유행성 병원체에 대한 지속적인 취약성에 직면한 가운데, 세균 백신이 다시 주목받고 있습니다. 이러한 백신은 이환율과 사망률을 예방하는 동시에 경험적 항균제 치료가 필요한 세균 감염의 발생률을 낮춤으로써 간접적으로 항생제 남용을 억제하는 이중의 역할을 합니다. 전 세계에서 AMR 위기에 대한 우려가 커지는 가운데, 세균 예방접종은 세균에 의한 질병 부담을 줄이고 항생제의 효과를 유지하기 위한 최전방 전략으로 점점 더 많이 인식되고 있습니다.

폐렴구균, 수막구균, 인플루엔자 b형(Hib), 백일해균과 같은 병원체가 지속적으로 위협을 가하고 있는 것은 세균성 백신 프로그램의 지속적인 중요성을 강조하고 있습니다. 지정학적 불안정성, 백신 접종에 대한 망설임, 의료 시스템의 혼란 등으로 인해 백신 접종률이 감소하고 지역 및 지방에서 발병이 발생함에 따라 정기 예방접종 인프라 구축 및 예방접종 캠페인에 대한 새로운 투자가 요구되고 있습니다. 세균 감염은 영유아, 노인, 면역력이 약한 집단에 불균형적으로 영향을 미치기 때문에 전 세계 공중보건 당국은 이러한 백신을 생애주기별 예방접종 프레임워크에 포함시키려고 노력하고 있습니다.

동시에 새로운 인수공통전염병과 약제 내성균의 위협은 연구개발의 모멘텀을 가속화하고 세계 백신 전략을 재구성하고 있습니다. 현재 각국 정부와 초국가적 기관들은 세균 백신의 비축과 표적화된 배포 계획을 보다 광범위한 대유행 대책의 틀에 포함시키려고 노력하고 있습니다. 이는 반응적 공중보건 태세에서 예방적 공중보건 태세로 전환하는 것을 의미하며, 세균 백신을 질병 예방의 수단으로서뿐만 아니라 세계 보건 안보 기반의 필수적인 요소로 자리매김하고 있습니다.

접합체 기술, 단백질 서브유닛 플랫폼, 보조제 혁신이 백신의 효능과 접종률을 어떻게 향상시키고 있는가?

결합형 백신 기술은 다당류 항원을 단백질 운반체에 결합시켜 인캡슐레이션된 박테리아에 대한 면역원성을 크게 향상시켜 보다 강력하고 지속적인 면역반응을 유도하는 기술입니다. 예를 들어 폐렴구균 결합 백신(PCV)은 소아에서 침습성 폐렴구균 질환을 극적으로 감소시켜 전체 인구에 군집 면역을 부여하고 있습니다. 우리는 현재도 예방 효과를 높이고, 물류 간소화, 의료 시스템의 부담을 줄이면서 예방 효과를 높이기 위해 혈청형 적용 범위를 확장하고 일정을 최적화하기 위해 노력하고 있습니다.

단백질 아단위 백신은 다당체 기반 접근법이 효과적이지 않은 병원균에 대해 널리 사용되고 있습니다. 정제된 박테리아 단백질 또는 톡소이드를 포함하는 이러한 제제는 강력한 안전성 프로파일과 함께 표적 면역 반응을 제공합니다. 백일해 백신, 디프테리아 백신, 파상풍 백신 등이 대표적인 예이며, 새로운 후보물질은 항원 드리프트에 대응하기 위해 균주 커버리지를 넓히고 항원 드리프트에 대응하기 위해 보존된 단백질 항원을 탐색하고 있습니다. 또한 새롭게 출현한 변종에 대응하여 서브유닛 제형을 신속하게 변경할 수 있게 됨에 따라 팬데믹(세계적 대유행) 상황에서 백신의 중요성도 커지고 있습니다.

AS01, MF59, CpG 올리고데옥시뉴클레오티드와 같은 새로운 보조제는 세포성 및 체액성 면역을 강화하고, 용량을 절약하고, 교차 방어 반응을 생성하는 등 하기 위해 통합되어 있습니다. 이러한 발전은 특히 성인 면역 시장과 부스터 면역 시장이 확대되고 있는 상황에서 지속적인 효능, 반응성 감소, 광범위한 인구에 대한 효능을 가진 차세대 박테리아 백신을 개발하는 데 있으며, 매우 중요합니다.

어떤 대상 집단, 질병의 우선순위, 정책적 요인이 세균 백신 접종 프로그램에 대한 수요를 형성하고 있는가?

특히 수막염, 폐렴, 패혈증, 백일해의 조기 예방을 우선시하는 국가의 예방접종 프로그램에서는 소아 인구가 여전히 주요 접종 대상입니다. 영유아기에 Hib, DTP, PCV를 광범위하게 접종함으로써 전 세계 아동 사망률은 특히 중저소득 국가(LMICs)에서 극적으로 감소했습니다. 그러나 백신 접근성 격차와 공급망 제한은 백신 접종에 영향을 미치고 있으며, GAVI와 WHO는 단계적 가격 책정 및 공동구매를 통해 형평성과 접근성을 개선하기 위한 노력을 지속하고 있습니다.

고령자 및 만성 합병증을 가진 사람은 세균성 폐렴, 균혈증, 병원내 감염에 취약하므로 대상자가 확대되고 있습니다. 폐렴구균, 디프테리아-파상풍-백일해(Tdap), 수막염균 부스터를 포함한 성인 예방접종 전략은 고소득 국가와 일부 LMIC에서 노인 인구의 의료 부담을 줄이고 질적 조정 생존 연수를 개선하기 위해 채택되고 있습니다. 독감 백신과 COVID-19 백신의 계절적 동시 접종 전략도 접종 효율성과 접종률 향상을 위해 평가되고 있습니다.

국가 예방접종 일정 개정부터 AMR 완화 계획까지 정책 구상은 세균 백신의 스케일업에 대한 기관 및 상업적 투자를 촉진하고 있습니다. 각국 정부는 질병 감시를 강화하고, 질병 감시를 강화하며, 추격전을 벌이고, 감염이 높은 지역에서 위험에 따라 예방접종을 실시했습니다. 이와 함께 여행 의료, 군 보건 프로그램, 발병 대응 프로토콜에 세균 백신을 선제적 대응책으로 도입하고 있습니다. 이러한 움직임으로 세균 백신은 공중보건, 비상사태 대비, 만성질환 관리의 영역을 넘나드는 툴로서 그 역할이 강화되고 있습니다.

세계 공급망 투자, 다량제제, 규제 혁신은 어떻게 시장 성장을 가속화하고 있는가?

세계 제조 및 콜드체인 인프라에 대한 전략적 투자로 인해, 특히 그동안 공급 제약으로 인해 접근성이 제한되었던 LMICs에서 세균성 백신에 대한 접근성을 확대할 수 있게 되었습니다. 공공-민간 파트너십, 첨단인 시장 약속, 기술이전 협정은 지역 백신 생산 허브를 활성화하고, 중앙 집중식 공급에 대한 의존도를 낮추며, 유통 기간을 단축하고 있습니다. 이러한 투자는 또한 보건 비상사태나 지정학적 혼란시 공급 충격에 대한 탄력성을 높이고 있습니다.

다가 백신으로의 전환은 예방접종 일정을 간소화하고 비용 효율성을 향상시킵니다. 여러 세균성 병원체를 표적으로 하는 혼합 백신(5가 및 6가 제제 등)은 주사의 부담을 줄이고 접종 순응도를 높이기 위해 소아과 프로그램에서 널리 사용되고 있습니다. 특히 폐렴구균, 장티푸스균, 임균과 같이 항원의 다양성이 백신 설계를 복잡하게 만드는 병원체에 대해는 한 가지 세균종으로 여러 균주를 표적으로 하는 광범위 후보물질의 개발에도 노력하고 있습니다.

규제 프레임워크는 안전성과 유효성을 훼손하지 않으면서 백신 개발 및 배포를 가속화하기 위해 진화하고 있습니다. 적응증 시험 설계, 실제 임상 증거의 통합, 신속 승인은 팬데믹 대응 및 일상적 사용 백신 시장 출시 시간을 단축하는 데 사용되고 있으며, WHO의 사전 승인 프로그램과 지역적 규제 조화 노력은 특히 의료 서비스를 받지 못하는 사람들과 세계 보건 우선순위를 대상으로 한 제품 시장 진입 경로를 강화하고 있습니다. 특히 의료 서비스를 받지 못하는 사람들과 전 세계 보건 우선순위를 대상으로 하는 제품 시장 진입 경로를 강화하고 있습니다.

장기적인 시장 전략에서 팬데믹 대응, AMR 완화, 신규 타겟 확대는 어떤 역할을 하는가?

세균 백신은 예르시니아 페스티스(Yersinia pestis), 버크홀데리아 슈도말레이(Burkholderia pseudomallei), 클로스트리디움 디피실(Clostridioides difficile) 등 유행 가능성이 있는 유행 가능성이 있는 병원체들을 중심으로 팬데믹 대응 전략의 중요한 요소로 부상하고 있습니다. 한편, 다자간 기구들은 원헬스 접근법(One Health Approach)에 따라 인간, 동물, 환경의 건강 위험을 연관시켜 백신의 우선순위를 정하는 프레임워크를 개발하고 있습니다.

세계에서 AMR 퇴치를 위한 노력이 강화되고 있는 가운데, 백신은 항생제 의존도를 줄이고 내성균의 발생을 늦추기 위한 업스트림 개입으로 자리매김하고 있습니다. 백신 접종은 항생제가 필요한 1차 감염을 예방하고, 간접적으로 항균제 노출과 내성 압력을 감소시킵니다. 이러한 역할은 AMR 국가행동계획에서 인정받고 있으며, 현재 임상 및 지역사회 환경에서 측정 가능한 목표로서 세균 백신 접종률을 포함하고 있습니다.

헬리코박터 파일로리, 대장균(요로병원성 및 장독소원성 균주), 이질균, 아시네토박터 바우마니 등 병원내 감염 병원체 등 미충족 수요에 대응하기 위해 세균 백신 파이프라인이 확대되고 있습니다. 이러한 노력은 기존 소아용 백신에서 성인용, 여행용, 병원내 감염 예방 시장으로 전략적으로 축을 옮기고 있는 것을 반영합니다. 비강 내, 경구, mRNA 기반 등 새로운 전달 플랫폼이 개발되고 있으며, 다양한 인구 집단에서 효능, 접근성, 수용성을 높이기 위해 개발되고 있습니다.

세균 백신 시장의 성장을 가속하는 요인은 무엇인가?

세균 백신 시장은 공중보건의 필요성, 항균제 청지기 정신, 국제 안보가 결합하여 풍토병과 신흥 위협에 대한 전략적 개입으로 예방접종을 강화함에 따라 성장하고 있습니다. 수요는 소아기 예방에 그치지 않고 성인, 여행, 병원내 진료 장면으로 확대되고 있습니다.

주요 성장 요인으로는 AMR에 대한 인식 증가, 예방접종 가이드라인 확대, 결합형 및 단백질 서브유닛 플랫폼의 기술 발전, 공평한 접근성 및 콜드체인 인프라에 대한 지속적인 투자 등을 들 수 있습니다. 파이프라인의 다양화, 정책 조정, 바이러스 백신과의 공동 투여를 통한 시너지 효과가 장기적인 모멘텀을 강화하고 있습니다.

항생제 피로와 건강 위험의 세계화 시대에 세균성 병원체가 그 연관성을 재인식하는 가운데, 백신은 공중보건의 툴로서뿐만 아니라 포스트 항생제 시대의 전신적 회복력의 정밀한 툴로서 감염병 대응의 미래를 재정의할 수 있는가?

부문

백신의 유형(백일해(Pertussis/Whooping Cough) 백신, 파상풍 백신, 디프테리아 백신, 폐렴구균 백신, 수막염균 백신, 장티푸스 백신, 결핵균 백신, 콜레라 백신, 세균성 이질 백신, 기타 백신), 환자 연령층(소아용 백신, 청소년용 백신, 성인용 백신, 노년용 백신), 투여 경로(근육내 투여, 정맥내 투여, 피하 투여, 기타 투여 경로), 판매채널(공적, 사적)

조사 대상 기업의 예(합계 37 주목 기업)

  • Astellas Pharma Inc.
  • AstraZeneca plc
  • Bavarian Nordic
  • Bharat Biotech
  • Biological E. Limited
  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb Company
  • CSL Limited(Seqirus)
  • Daiichi Sankyo Company, Limited
  • Emergent BioSolutions Inc.
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline plc(GSK)
  • Indian Immunologicals Ltd.
  • Johnson & Johnson
  • KM Biologics Co., Ltd.
  • LG Chem Ltd.
  • Merck & Co., Inc.
  • Mitsubishi Tanabe Pharma Corporation
  • Mylan N.V.
  • Novartis AG

관세 영향 계수

Global Industry Analysts는 본사의 국가, 제조거점, 수출입(완제품 및 OEM)을 기반으로 기업의 경쟁력 변화를 예측했습니다. 이러한 복잡하고 다면적인 시장 역학은 인위적인 수입원가 증가, 수익성 감소, 공급망 재편 등 미시적 및 거시적 시장 역학 중에서도 특히 경쟁사들에게 영향을 미칠 것으로 예측됩니다.

Global Industry Analysts는 세계 주요 수석 이코노미스트(1,4,949명), 싱크탱크(62개 기관), 무역 및 산업 단체(171개 기관)의 전문가들의 의견을 면밀히 검토하여 생태계에 미치는 영향을 평가하고 새로운 시장 현실에 대응하고 있습니다. 모든 주요 국가의 전문가와 경제학자들이 관세와 그것이 자국에 미치는 영향에 대한 의견을 추적 조사했습니다.

Global Industry Analysts는 이러한 혼란이 향후 2-3개월 내에 마무리되고 새로운 세계 질서가 보다 명확하게 확립될 것으로 예상하고 있으며, Global Industry Analysts는 이러한 상황을 실시간으로 추적하고 있습니다.

2025년 4월: 협상 단계

이번 4월 보고서에서는 관세가 세계 시장 전체에 미치는 영향과 지역별 시장 조정에 대해 소개합니다. 당사의 예측은 과거 데이터와 진화하는 시장 영향요인을 기반으로 합니다.

2025년 7월: 최종 관세 재설정

고객님들께는 각 국가별 최종 리셋이 발표된 후 7월에 무료 업데이트 버전을 제공해 드립니다. 최종 업데이트 버전에는 명확하게 정의된 관세 영향 분석이 포함되어 있습니다.

상호 및 양자 간 무역과 관세의 영향 분석 :

미국 <>중국 <>멕시코 <>캐나다 <>EU <>일본 <>인도 <>기타 176개국

업계 최고의 이코노미스트: Global Industry Analysts의 지식 기반은 국가, 싱크탱크, 무역 및 산업 단체, 대기업, 그리고 세계 계량 경제 상황의 전례 없는 패러다임 전환의 영향을 공유하는 분야별 전문가 등 가장 영향력 있는 수석 이코노미스트 그룹을 포함한 14,949명의 이코노미스트를 추적하고 있습니다. 16,491개 이상의 보고서 대부분에 마일스톤에 기반한 2단계 출시 일정이 적용되어 있습니다.

목차

제1장 조사 방법

제2장 개요

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트
  • 기타 중동
  • 아프리카

제4장 경쟁

KSA 25.06.18

Global Bacterial Vaccines Market to Reach US$35.8 Billion by 2030

The global market for Bacterial Vaccines estimated at US$24.9 Billion in the year 2024, is expected to reach US$35.8 Billion by 2030, growing at a CAGR of 6.2% over the analysis period 2024-2030. Pertussis / Whooping Cough Vaccines, one of the segments analyzed in the report, is expected to record a 5.0% CAGR and reach US$9.2 Billion by the end of the analysis period. Growth in the Other Vaccine Types segment is estimated at 4.5% CAGR over the analysis period.

The U.S. Market is Estimated at US$6.8 Billion While China is Forecast to Grow at 9.6% CAGR

The Bacterial Vaccines market in the U.S. is estimated at US$6.8 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$7.2 Billion by the year 2030 trailing a CAGR of 9.6% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.2% and 6.0% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.1% CAGR.

Global Bacterial Vaccines Market - Key Trends & Drivers Summarized

Why Are Bacterial Vaccines Re-Emerging as Strategic Assets in Infectious Disease Control, Antimicrobial Resistance Mitigation, and Global Health Preparedness?

Bacterial vaccines are regaining prominence as global health systems confront rising antimicrobial resistance (AMR), resurgence of vaccine-preventable diseases, and ongoing vulnerability to epidemic-prone pathogens. These vaccines play a dual role in preventing morbidity and mortality while indirectly curbing antibiotic overuse by reducing the incidence of bacterial infections that often prompt empirical antimicrobial treatment. Amid growing concern over the global AMR crisis, bacterial immunization is increasingly recognized as a frontline strategy for reducing bacterial disease burden and preserving antibiotic efficacy.

The continued threat posed by pathogens such as Streptococcus pneumoniae, Neisseria meningitidis, Haemophilus influenzae type b (Hib), and Bordetella pertussis underscores the enduring importance of bacterial vaccine programs. Vaccination coverage gaps-driven by geopolitical instability, vaccine hesitancy, and health system disruptions-have led to local and regional outbreaks, prompting renewed investments in routine immunization infrastructure and booster campaigns. As bacterial infections disproportionately affect infants, the elderly, and immunocompromised populations, these vaccines are being integrated into life-course immunization frameworks by global public health authorities.

Simultaneously, emerging zoonotic and drug-resistant bacterial threats are accelerating R&D momentum and reshaping global vaccine strategies. Governments and supranational agencies are now incorporating bacterial vaccine stockpiles and targeted rollout plans into broader pandemic preparedness frameworks. This marks a shift from reactive to preventive public health postures, positioning bacterial vaccines not only as tools of disease prevention but also as essential elements of global health security infrastructure.

How Are Conjugate Technologies, Protein Subunit Platforms, and Adjuvant Innovation Advancing Vaccine Efficacy and Coverage?

Conjugate vaccine technologies have significantly improved immunogenicity against encapsulated bacteria by linking polysaccharide antigens to protein carriers, eliciting stronger and longer-lasting immune responses. Pneumococcal conjugate vaccines (PCVs), for example, have dramatically reduced invasive pneumococcal disease in children and conferred herd immunity across populations. Ongoing efforts are focused on expanding serotype coverage and optimizing schedules to enhance protection while simplifying logistics and reducing healthcare system burdens.

Protein subunit vaccines are gaining traction for pathogens where polysaccharide-based approaches are less effective. These formulations, which include purified bacterial proteins or toxoids, offer targeted immune responses with strong safety profiles. Pertussis, diphtheria, and tetanus vaccines are key examples, and newer candidates are exploring conserved protein antigens to broaden strain coverage and address antigenic drift. The ability to rapidly modify subunit formulations in response to emerging variants is also strengthening their relevance in pandemic contexts.

Adjuvant innovation is further enhancing bacterial vaccine performance, particularly in older adults and immunologically challenged individuals. Novel adjuvants-such as AS01, MF59, and CpG oligodeoxynucleotides-are being incorporated to boost cellular and humoral immunity, improve dose-sparing, and generate cross-protective responses. These advances are critical for developing next-generation bacterial vaccines with durable efficacy, reduced reactogenicity, and broader population reach, especially in the context of expanding adult and booster immunization markets.

Which Target Populations, Disease Priorities, and Policy Drivers Are Shaping Demand for Bacterial Vaccination Programs?

Pediatric populations remain the core recipients of bacterial vaccines, particularly in national immunization programs that prioritize early protection against meningitis, pneumonia, sepsis, and pertussis. Widespread administration of Hib, DTP, and PCV in infancy has dramatically reduced global child mortality, especially in low- and middle-income countries (LMICs). However, disparities in access and supply chain limitations continue to influence vaccine uptake, driving efforts by Gavi and WHO to improve equity and affordability through tiered pricing and pooled procurement.

Elderly adults and individuals with chronic comorbidities are an expanding target group due to their heightened susceptibility to bacterial pneumonia, bacteremia, and hospital-acquired infections. Adult immunization strategies-including pneumococcal, diphtheria-tetanus-pertussis (Tdap), and meningococcal boosters-are being adopted by high-income nations and select LMICs to reduce healthcare burden and improve quality-adjusted life years (QALYs) among aging populations. Seasonal co-administration strategies with influenza or COVID-19 vaccines are also under evaluation to streamline delivery and improve coverage.

Policy initiatives-ranging from national immunization schedule revisions to AMR mitigation plans-are driving institutional and commercial investment in bacterial vaccine scale-up. Governments are strengthening disease surveillance, catch-up campaigns, and risk-based immunization in high-transmission zones. In parallel, travel medicine, military health programs, and outbreak response protocols are incorporating bacterial vaccines as pre-emptive measures. These dynamics are reinforcing the role of bacterial vaccines as cross-cutting tools across public health, emergency preparedness, and chronic disease management domains.

How Are Global Supply Chain Investments, Multivalent Formulations, and Regulatory Innovation Accelerating Market Growth?

Strategic investments in global manufacturing and cold-chain infrastructure are enabling expanded access to bacterial vaccines, particularly in LMICs where delivery constraints have historically limited coverage. Public-private partnerships, advanced market commitments, and tech-transfer agreements are catalyzing regional vaccine production hubs to reduce reliance on centralized supply and shorten distribution timelines. These investments are also fostering greater resilience against supply shocks during health emergencies or geopolitical disruptions.

The push toward multivalent formulations is streamlining immunization schedules and improving cost-efficiency. Combination vaccines targeting multiple bacterial pathogens-such as pentavalent and hexavalent formulations-are being widely adopted in pediatric programs to reduce injection burden and improve compliance. Development efforts are also underway for broad-spectrum candidates that target multiple strains within a single bacterial species, particularly for pathogens like Streptococcus pneumoniae, Salmonella typhi, and Neisseria gonorrhoeae where antigenic diversity complicates vaccine design.

Regulatory frameworks are evolving to expedite vaccine development and rollout without compromising safety or efficacy. Adaptive trial designs, real-world evidence integration, and fast-track approvals are being used to accelerate time-to-market for both pandemic-responsive and routine-use bacterial vaccines. The WHO prequalification program and regional regulatory harmonization efforts are also enhancing market entry pathways, especially for products targeting underserved populations and global health priorities.

What Role Do Pandemic Preparedness, AMR Mitigation, and Novel Target Expansion Play in Long-Term Market Strategy?

Bacterial vaccines are emerging as critical components of pandemic preparedness strategies, with a focus on pathogens with epidemic potential such as Yersinia pestis, Burkholderia pseudomallei, and Clostridioides difficile. Government funding mechanisms and biodefense programs are supporting R&D for these high-risk agents, while multilateral organizations are developing vaccine prioritization frameworks under the One Health approach-linking human, animal, and environmental health risks.

As global efforts to combat AMR intensify, vaccines are being positioned as upstream interventions to reduce antibiotic reliance and slow resistance development. Vaccination prevents primary infections that would otherwise require antibiotics, indirectly reducing antimicrobial exposure and resistance pressure. This role is gaining recognition in AMR national action plans, which now include bacterial immunization coverage as a measurable objective in both clinical and community settings.

The bacterial vaccine pipeline is expanding to address unmet needs such as Helicobacter pylori, Escherichia coli (for uropathogenic and enterotoxigenic strains), Shigella, and hospital-acquired pathogens like Acinetobacter baumannii. These efforts reflect a broader strategic pivot from traditional childhood vaccines toward adult, travel, and nosocomial prevention markets. Novel delivery platforms-including intranasal, oral, and mRNA-based bacterial vaccines-are under development to enhance efficacy, accessibility, and acceptance in varied population segments.

What Are the Factors Driving Growth in the Bacterial Vaccines Market?

The bacterial vaccines market is growing as public health imperatives, antimicrobial stewardship, and global health security converge to elevate immunization as a strategic intervention against both endemic and emerging threats. Demand is expanding beyond childhood prevention into adult, travel, and nosocomial care settings.

Key growth drivers include rising AMR awareness, expanded immunization guidelines, technological advancements in conjugate and protein subunit platforms, and ongoing investments in equitable access and cold-chain infrastructure. Pipeline diversification, policy alignment, and co-administration synergies with viral vaccines are reinforcing long-term momentum.

As bacterial pathogens reassert their relevance in an era of antibiotic fatigue and globalized health risks, could vaccines redefine the future of infectious disease control-not just as public health tools, but as precision instruments of systemic resilience in the post-antibiotic age?

SCOPE OF STUDY:

The report analyzes the Bacterial Vaccines market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Vaccine Type (Pertussis / Whooping Cough Vaccines, Tetanus Vaccines, Diphtheria Vaccines, Pneumococcal Vaccines, Meningococcal Vaccines, Typhoid Vaccines, Tuberculosis Vaccines, Cholera Vaccines, Shigellosis Vaccines, Other Vaccine Types); Patient Age Group (Pediatric Vaccines, Adolescent Vaccines, Adult Vaccines, Geriatric Vaccines); Administration Route (Intramuscular, Intravenous, Subcutaneous, Other Administration Routes); Distribution Channel (Public, Private)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 37 Featured) -

  • Astellas Pharma Inc.
  • AstraZeneca plc
  • Bavarian Nordic
  • Bharat Biotech
  • Biological E. Limited
  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb Company
  • CSL Limited (Seqirus)
  • Daiichi Sankyo Company, Limited
  • Emergent BioSolutions Inc.
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline plc (GSK)
  • Indian Immunologicals Ltd.
  • Johnson & Johnson
  • KM Biologics Co., Ltd.
  • LG Chem Ltd.
  • Merck & Co., Inc.
  • Mitsubishi Tanabe Pharma Corporation
  • Mylan N.V.
  • Novartis AG

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA <> CHINA <> MEXICO <> CANADA <> EU <> JAPAN <> INDIA <> 176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

COMPLIMENTARY PREVIEW

Contact your sales agent to request an online 300+ page complimentary preview of this research project. Our preview will present full stack sources, and validated domain expert data transcripts. Deep dive into our interactive data-driven online platform.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Bacterial Vaccines - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Prevalence of Antibiotic-Resistant Infections Throws the Spotlight on Bacterial Vaccines
    • Growth in Immunization Programs Against Meningococcal, Pneumococcal, and Pertussis Infections Spurs Market Expansion
    • OEM Innovation in Conjugate and Recombinant Protein Vaccines Enhances Immunogenicity and Safety Profiles
    • Increased Demand for Adult and Geriatric Immunization Supports Expansion Beyond Pediatric Coverage
    • Use of mRNA and DNA Technologies for Bacterial Targets Accelerates Development Timelines
    • Public-Private Partnerships Drive Clinical Trials and Global Access to High-Priority Vaccines
    • Integration With National Immunization Registries Supports Dose Scheduling and Adherence
    • OEMs Targeting Multivalent and Combination Formulations Improve Compliance and Delivery Efficiency
    • Rise in Antimicrobial Stewardship Programs Encourages Vaccine-Driven Infection Control Strategies
    • Emerging Threats Like C. difficile and H. pylori Infection Spur Niche Vaccine Pipeline Growth
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Bacterial Vaccines Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Bacterial Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Bacterial Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Bacterial Vaccines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Pertussis / Whooping Cough Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Pertussis / Whooping Cough Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Pertussis / Whooping Cough Vaccines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Other Vaccine Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Other Vaccine Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Other Vaccine Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Tetanus Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Tetanus Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Tetanus Vaccines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Diphtheria Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Diphtheria Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Diphtheria Vaccines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Pneumococcal Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Pneumococcal Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Pneumococcal Vaccines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Meningococcal Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Meningococcal Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 22: World 15-Year Perspective for Meningococcal Vaccines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Typhoid Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Typhoid Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 25: World 15-Year Perspective for Typhoid Vaccines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Tuberculosis Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Tuberculosis Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 28: World 15-Year Perspective for Tuberculosis Vaccines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Cholera Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Cholera Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 31: World 15-Year Perspective for Cholera Vaccines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 32: World Recent Past, Current & Future Analysis for Shigellosis Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 33: World Historic Review for Shigellosis Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 34: World 15-Year Perspective for Shigellosis Vaccines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 35: World Recent Past, Current & Future Analysis for Pediatric Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 36: World Historic Review for Pediatric Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 37: World 15-Year Perspective for Pediatric Vaccines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 38: World Recent Past, Current & Future Analysis for Adolescent Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 39: World Historic Review for Adolescent Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 40: World 15-Year Perspective for Adolescent Vaccines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 41: World Recent Past, Current & Future Analysis for Adult Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 42: World Historic Review for Adult Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 43: World 15-Year Perspective for Adult Vaccines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 44: World Recent Past, Current & Future Analysis for Geriatric Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 45: World Historic Review for Geriatric Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 46: World 15-Year Perspective for Geriatric Vaccines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 47: World Recent Past, Current & Future Analysis for Intramuscular by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 48: World Historic Review for Intramuscular by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 49: World 15-Year Perspective for Intramuscular by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 50: World Recent Past, Current & Future Analysis for Intravenous by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 51: World Historic Review for Intravenous by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 52: World 15-Year Perspective for Intravenous by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 53: World Recent Past, Current & Future Analysis for Subcutaneous by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 54: World Historic Review for Subcutaneous by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 55: World 15-Year Perspective for Subcutaneous by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 56: World Recent Past, Current & Future Analysis for Other Administration Routes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 57: World Historic Review for Other Administration Routes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 58: World 15-Year Perspective for Other Administration Routes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 59: World Recent Past, Current & Future Analysis for Public by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 60: World Historic Review for Public by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 61: World 15-Year Perspective for Public by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 62: World Recent Past, Current & Future Analysis for Private by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 63: World Historic Review for Private by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 64: World 15-Year Perspective for Private by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Bacterial Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 65: USA Recent Past, Current & Future Analysis for Bacterial Vaccines by Vaccine Type - Pertussis / Whooping Cough Vaccines, Other Vaccine Types, Tetanus Vaccines, Diphtheria Vaccines, Pneumococcal Vaccines, Meningococcal Vaccines, Typhoid Vaccines, Tuberculosis Vaccines, Cholera Vaccines and Shigellosis Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: USA Historic Review for Bacterial Vaccines by Vaccine Type - Pertussis / Whooping Cough Vaccines, Other Vaccine Types, Tetanus Vaccines, Diphtheria Vaccines, Pneumococcal Vaccines, Meningococcal Vaccines, Typhoid Vaccines, Tuberculosis Vaccines, Cholera Vaccines and Shigellosis Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 67: USA 15-Year Perspective for Bacterial Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Pertussis / Whooping Cough Vaccines, Other Vaccine Types, Tetanus Vaccines, Diphtheria Vaccines, Pneumococcal Vaccines, Meningococcal Vaccines, Typhoid Vaccines, Tuberculosis Vaccines, Cholera Vaccines and Shigellosis Vaccines for the Years 2015, 2025 & 2030
    • TABLE 68: USA Recent Past, Current & Future Analysis for Bacterial Vaccines by Patient Age Group - Pediatric Vaccines, Adolescent Vaccines, Adult Vaccines and Geriatric Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: USA Historic Review for Bacterial Vaccines by Patient Age Group - Pediatric Vaccines, Adolescent Vaccines, Adult Vaccines and Geriatric Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 70: USA 15-Year Perspective for Bacterial Vaccines by Patient Age Group - Percentage Breakdown of Value Sales for Pediatric Vaccines, Adolescent Vaccines, Adult Vaccines and Geriatric Vaccines for the Years 2015, 2025 & 2030
    • TABLE 71: USA Recent Past, Current & Future Analysis for Bacterial Vaccines by Administration Route - Intramuscular, Intravenous, Subcutaneous and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: USA Historic Review for Bacterial Vaccines by Administration Route - Intramuscular, Intravenous, Subcutaneous and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 73: USA 15-Year Perspective for Bacterial Vaccines by Administration Route - Percentage Breakdown of Value Sales for Intramuscular, Intravenous, Subcutaneous and Other Administration Routes for the Years 2015, 2025 & 2030
    • TABLE 74: USA Recent Past, Current & Future Analysis for Bacterial Vaccines by Distribution Channel - Public and Private - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: USA Historic Review for Bacterial Vaccines by Distribution Channel - Public and Private Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 76: USA 15-Year Perspective for Bacterial Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Public and Private for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 77: Canada Recent Past, Current & Future Analysis for Bacterial Vaccines by Vaccine Type - Pertussis / Whooping Cough Vaccines, Other Vaccine Types, Tetanus Vaccines, Diphtheria Vaccines, Pneumococcal Vaccines, Meningococcal Vaccines, Typhoid Vaccines, Tuberculosis Vaccines, Cholera Vaccines and Shigellosis Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Canada Historic Review for Bacterial Vaccines by Vaccine Type - Pertussis / Whooping Cough Vaccines, Other Vaccine Types, Tetanus Vaccines, Diphtheria Vaccines, Pneumococcal Vaccines, Meningococcal Vaccines, Typhoid Vaccines, Tuberculosis Vaccines, Cholera Vaccines and Shigellosis Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 79: Canada 15-Year Perspective for Bacterial Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Pertussis / Whooping Cough Vaccines, Other Vaccine Types, Tetanus Vaccines, Diphtheria Vaccines, Pneumococcal Vaccines, Meningococcal Vaccines, Typhoid Vaccines, Tuberculosis Vaccines, Cholera Vaccines and Shigellosis Vaccines for the Years 2015, 2025 & 2030
    • TABLE 80: Canada Recent Past, Current & Future Analysis for Bacterial Vaccines by Patient Age Group - Pediatric Vaccines, Adolescent Vaccines, Adult Vaccines and Geriatric Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Canada Historic Review for Bacterial Vaccines by Patient Age Group - Pediatric Vaccines, Adolescent Vaccines, Adult Vaccines and Geriatric Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 82: Canada 15-Year Perspective for Bacterial Vaccines by Patient Age Group - Percentage Breakdown of Value Sales for Pediatric Vaccines, Adolescent Vaccines, Adult Vaccines and Geriatric Vaccines for the Years 2015, 2025 & 2030
    • TABLE 83: Canada Recent Past, Current & Future Analysis for Bacterial Vaccines by Administration Route - Intramuscular, Intravenous, Subcutaneous and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Canada Historic Review for Bacterial Vaccines by Administration Route - Intramuscular, Intravenous, Subcutaneous and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 85: Canada 15-Year Perspective for Bacterial Vaccines by Administration Route - Percentage Breakdown of Value Sales for Intramuscular, Intravenous, Subcutaneous and Other Administration Routes for the Years 2015, 2025 & 2030
    • TABLE 86: Canada Recent Past, Current & Future Analysis for Bacterial Vaccines by Distribution Channel - Public and Private - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Canada Historic Review for Bacterial Vaccines by Distribution Channel - Public and Private Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 88: Canada 15-Year Perspective for Bacterial Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Public and Private for the Years 2015, 2025 & 2030
  • JAPAN
    • Bacterial Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 89: Japan Recent Past, Current & Future Analysis for Bacterial Vaccines by Vaccine Type - Pertussis / Whooping Cough Vaccines, Other Vaccine Types, Tetanus Vaccines, Diphtheria Vaccines, Pneumococcal Vaccines, Meningococcal Vaccines, Typhoid Vaccines, Tuberculosis Vaccines, Cholera Vaccines and Shigellosis Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Japan Historic Review for Bacterial Vaccines by Vaccine Type - Pertussis / Whooping Cough Vaccines, Other Vaccine Types, Tetanus Vaccines, Diphtheria Vaccines, Pneumococcal Vaccines, Meningococcal Vaccines, Typhoid Vaccines, Tuberculosis Vaccines, Cholera Vaccines and Shigellosis Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 91: Japan 15-Year Perspective for Bacterial Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Pertussis / Whooping Cough Vaccines, Other Vaccine Types, Tetanus Vaccines, Diphtheria Vaccines, Pneumococcal Vaccines, Meningococcal Vaccines, Typhoid Vaccines, Tuberculosis Vaccines, Cholera Vaccines and Shigellosis Vaccines for the Years 2015, 2025 & 2030
    • TABLE 92: Japan Recent Past, Current & Future Analysis for Bacterial Vaccines by Patient Age Group - Pediatric Vaccines, Adolescent Vaccines, Adult Vaccines and Geriatric Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Japan Historic Review for Bacterial Vaccines by Patient Age Group - Pediatric Vaccines, Adolescent Vaccines, Adult Vaccines and Geriatric Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 94: Japan 15-Year Perspective for Bacterial Vaccines by Patient Age Group - Percentage Breakdown of Value Sales for Pediatric Vaccines, Adolescent Vaccines, Adult Vaccines and Geriatric Vaccines for the Years 2015, 2025 & 2030
    • TABLE 95: Japan Recent Past, Current & Future Analysis for Bacterial Vaccines by Administration Route - Intramuscular, Intravenous, Subcutaneous and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Japan Historic Review for Bacterial Vaccines by Administration Route - Intramuscular, Intravenous, Subcutaneous and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 97: Japan 15-Year Perspective for Bacterial Vaccines by Administration Route - Percentage Breakdown of Value Sales for Intramuscular, Intravenous, Subcutaneous and Other Administration Routes for the Years 2015, 2025 & 2030
    • TABLE 98: Japan Recent Past, Current & Future Analysis for Bacterial Vaccines by Distribution Channel - Public and Private - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Japan Historic Review for Bacterial Vaccines by Distribution Channel - Public and Private Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 100: Japan 15-Year Perspective for Bacterial Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Public and Private for the Years 2015, 2025 & 2030
  • CHINA
    • Bacterial Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 101: China Recent Past, Current & Future Analysis for Bacterial Vaccines by Vaccine Type - Pertussis / Whooping Cough Vaccines, Other Vaccine Types, Tetanus Vaccines, Diphtheria Vaccines, Pneumococcal Vaccines, Meningococcal Vaccines, Typhoid Vaccines, Tuberculosis Vaccines, Cholera Vaccines and Shigellosis Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: China Historic Review for Bacterial Vaccines by Vaccine Type - Pertussis / Whooping Cough Vaccines, Other Vaccine Types, Tetanus Vaccines, Diphtheria Vaccines, Pneumococcal Vaccines, Meningococcal Vaccines, Typhoid Vaccines, Tuberculosis Vaccines, Cholera Vaccines and Shigellosis Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 103: China 15-Year Perspective for Bacterial Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Pertussis / Whooping Cough Vaccines, Other Vaccine Types, Tetanus Vaccines, Diphtheria Vaccines, Pneumococcal Vaccines, Meningococcal Vaccines, Typhoid Vaccines, Tuberculosis Vaccines, Cholera Vaccines and Shigellosis Vaccines for the Years 2015, 2025 & 2030
    • TABLE 104: China Recent Past, Current & Future Analysis for Bacterial Vaccines by Patient Age Group - Pediatric Vaccines, Adolescent Vaccines, Adult Vaccines and Geriatric Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: China Historic Review for Bacterial Vaccines by Patient Age Group - Pediatric Vaccines, Adolescent Vaccines, Adult Vaccines and Geriatric Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 106: China 15-Year Perspective for Bacterial Vaccines by Patient Age Group - Percentage Breakdown of Value Sales for Pediatric Vaccines, Adolescent Vaccines, Adult Vaccines and Geriatric Vaccines for the Years 2015, 2025 & 2030
    • TABLE 107: China Recent Past, Current & Future Analysis for Bacterial Vaccines by Administration Route - Intramuscular, Intravenous, Subcutaneous and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: China Historic Review for Bacterial Vaccines by Administration Route - Intramuscular, Intravenous, Subcutaneous and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 109: China 15-Year Perspective for Bacterial Vaccines by Administration Route - Percentage Breakdown of Value Sales for Intramuscular, Intravenous, Subcutaneous and Other Administration Routes for the Years 2015, 2025 & 2030
    • TABLE 110: China Recent Past, Current & Future Analysis for Bacterial Vaccines by Distribution Channel - Public and Private - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: China Historic Review for Bacterial Vaccines by Distribution Channel - Public and Private Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 112: China 15-Year Perspective for Bacterial Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Public and Private for the Years 2015, 2025 & 2030
  • EUROPE
    • Bacterial Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 113: Europe Recent Past, Current & Future Analysis for Bacterial Vaccines by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 114: Europe Historic Review for Bacterial Vaccines by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 115: Europe 15-Year Perspective for Bacterial Vaccines by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 116: Europe Recent Past, Current & Future Analysis for Bacterial Vaccines by Vaccine Type - Pertussis / Whooping Cough Vaccines, Other Vaccine Types, Tetanus Vaccines, Diphtheria Vaccines, Pneumococcal Vaccines, Meningococcal Vaccines, Typhoid Vaccines, Tuberculosis Vaccines, Cholera Vaccines and Shigellosis Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Europe Historic Review for Bacterial Vaccines by Vaccine Type - Pertussis / Whooping Cough Vaccines, Other Vaccine Types, Tetanus Vaccines, Diphtheria Vaccines, Pneumococcal Vaccines, Meningococcal Vaccines, Typhoid Vaccines, Tuberculosis Vaccines, Cholera Vaccines and Shigellosis Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 118: Europe 15-Year Perspective for Bacterial Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Pertussis / Whooping Cough Vaccines, Other Vaccine Types, Tetanus Vaccines, Diphtheria Vaccines, Pneumococcal Vaccines, Meningococcal Vaccines, Typhoid Vaccines, Tuberculosis Vaccines, Cholera Vaccines and Shigellosis Vaccines for the Years 2015, 2025 & 2030
    • TABLE 119: Europe Recent Past, Current & Future Analysis for Bacterial Vaccines by Patient Age Group - Pediatric Vaccines, Adolescent Vaccines, Adult Vaccines and Geriatric Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: Europe Historic Review for Bacterial Vaccines by Patient Age Group - Pediatric Vaccines, Adolescent Vaccines, Adult Vaccines and Geriatric Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 121: Europe 15-Year Perspective for Bacterial Vaccines by Patient Age Group - Percentage Breakdown of Value Sales for Pediatric Vaccines, Adolescent Vaccines, Adult Vaccines and Geriatric Vaccines for the Years 2015, 2025 & 2030
    • TABLE 122: Europe Recent Past, Current & Future Analysis for Bacterial Vaccines by Administration Route - Intramuscular, Intravenous, Subcutaneous and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Europe Historic Review for Bacterial Vaccines by Administration Route - Intramuscular, Intravenous, Subcutaneous and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 124: Europe 15-Year Perspective for Bacterial Vaccines by Administration Route - Percentage Breakdown of Value Sales for Intramuscular, Intravenous, Subcutaneous and Other Administration Routes for the Years 2015, 2025 & 2030
    • TABLE 125: Europe Recent Past, Current & Future Analysis for Bacterial Vaccines by Distribution Channel - Public and Private - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Europe Historic Review for Bacterial Vaccines by Distribution Channel - Public and Private Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 127: Europe 15-Year Perspective for Bacterial Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Public and Private for the Years 2015, 2025 & 2030
  • FRANCE
    • Bacterial Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 128: France Recent Past, Current & Future Analysis for Bacterial Vaccines by Vaccine Type - Pertussis / Whooping Cough Vaccines, Other Vaccine Types, Tetanus Vaccines, Diphtheria Vaccines, Pneumococcal Vaccines, Meningococcal Vaccines, Typhoid Vaccines, Tuberculosis Vaccines, Cholera Vaccines and Shigellosis Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: France Historic Review for Bacterial Vaccines by Vaccine Type - Pertussis / Whooping Cough Vaccines, Other Vaccine Types, Tetanus Vaccines, Diphtheria Vaccines, Pneumococcal Vaccines, Meningococcal Vaccines, Typhoid Vaccines, Tuberculosis Vaccines, Cholera Vaccines and Shigellosis Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 130: France 15-Year Perspective for Bacterial Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Pertussis / Whooping Cough Vaccines, Other Vaccine Types, Tetanus Vaccines, Diphtheria Vaccines, Pneumococcal Vaccines, Meningococcal Vaccines, Typhoid Vaccines, Tuberculosis Vaccines, Cholera Vaccines and Shigellosis Vaccines for the Years 2015, 2025 & 2030
    • TABLE 131: France Recent Past, Current & Future Analysis for Bacterial Vaccines by Patient Age Group - Pediatric Vaccines, Adolescent Vaccines, Adult Vaccines and Geriatric Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: France Historic Review for Bacterial Vaccines by Patient Age Group - Pediatric Vaccines, Adolescent Vaccines, Adult Vaccines and Geriatric Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 133: France 15-Year Perspective for Bacterial Vaccines by Patient Age Group - Percentage Breakdown of Value Sales for Pediatric Vaccines, Adolescent Vaccines, Adult Vaccines and Geriatric Vaccines for the Years 2015, 2025 & 2030
    • TABLE 134: France Recent Past, Current & Future Analysis for Bacterial Vaccines by Administration Route - Intramuscular, Intravenous, Subcutaneous and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 135: France Historic Review for Bacterial Vaccines by Administration Route - Intramuscular, Intravenous, Subcutaneous and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 136: France 15-Year Perspective for Bacterial Vaccines by Administration Route - Percentage Breakdown of Value Sales for Intramuscular, Intravenous, Subcutaneous and Other Administration Routes for the Years 2015, 2025 & 2030
    • TABLE 137: France Recent Past, Current & Future Analysis for Bacterial Vaccines by Distribution Channel - Public and Private - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 138: France Historic Review for Bacterial Vaccines by Distribution Channel - Public and Private Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 139: France 15-Year Perspective for Bacterial Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Public and Private for the Years 2015, 2025 & 2030
  • GERMANY
    • Bacterial Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 140: Germany Recent Past, Current & Future Analysis for Bacterial Vaccines by Vaccine Type - Pertussis / Whooping Cough Vaccines, Other Vaccine Types, Tetanus Vaccines, Diphtheria Vaccines, Pneumococcal Vaccines, Meningococcal Vaccines, Typhoid Vaccines, Tuberculosis Vaccines, Cholera Vaccines and Shigellosis Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Germany Historic Review for Bacterial Vaccines by Vaccine Type - Pertussis / Whooping Cough Vaccines, Other Vaccine Types, Tetanus Vaccines, Diphtheria Vaccines, Pneumococcal Vaccines, Meningococcal Vaccines, Typhoid Vaccines, Tuberculosis Vaccines, Cholera Vaccines and Shigellosis Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 142: Germany 15-Year Perspective for Bacterial Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Pertussis / Whooping Cough Vaccines, Other Vaccine Types, Tetanus Vaccines, Diphtheria Vaccines, Pneumococcal Vaccines, Meningococcal Vaccines, Typhoid Vaccines, Tuberculosis Vaccines, Cholera Vaccines and Shigellosis Vaccines for the Years 2015, 2025 & 2030
    • TABLE 143: Germany Recent Past, Current & Future Analysis for Bacterial Vaccines by Patient Age Group - Pediatric Vaccines, Adolescent Vaccines, Adult Vaccines and Geriatric Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Germany Historic Review for Bacterial Vaccines by Patient Age Group - Pediatric Vaccines, Adolescent Vaccines, Adult Vaccines and Geriatric Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 145: Germany 15-Year Perspective for Bacterial Vaccines by Patient Age Group - Percentage Breakdown of Value Sales for Pediatric Vaccines, Adolescent Vaccines, Adult Vaccines and Geriatric Vaccines for the Years 2015, 2025 & 2030
    • TABLE 146: Germany Recent Past, Current & Future Analysis for Bacterial Vaccines by Administration Route - Intramuscular, Intravenous, Subcutaneous and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Germany Historic Review for Bacterial Vaccines by Administration Route - Intramuscular, Intravenous, Subcutaneous and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 148: Germany 15-Year Perspective for Bacterial Vaccines by Administration Route - Percentage Breakdown of Value Sales for Intramuscular, Intravenous, Subcutaneous and Other Administration Routes for the Years 2015, 2025 & 2030
    • TABLE 149: Germany Recent Past, Current & Future Analysis for Bacterial Vaccines by Distribution Channel - Public and Private - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Germany Historic Review for Bacterial Vaccines by Distribution Channel - Public and Private Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 151: Germany 15-Year Perspective for Bacterial Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Public and Private for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 152: Italy Recent Past, Current & Future Analysis for Bacterial Vaccines by Vaccine Type - Pertussis / Whooping Cough Vaccines, Other Vaccine Types, Tetanus Vaccines, Diphtheria Vaccines, Pneumococcal Vaccines, Meningococcal Vaccines, Typhoid Vaccines, Tuberculosis Vaccines, Cholera Vaccines and Shigellosis Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Italy Historic Review for Bacterial Vaccines by Vaccine Type - Pertussis / Whooping Cough Vaccines, Other Vaccine Types, Tetanus Vaccines, Diphtheria Vaccines, Pneumococcal Vaccines, Meningococcal Vaccines, Typhoid Vaccines, Tuberculosis Vaccines, Cholera Vaccines and Shigellosis Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 154: Italy 15-Year Perspective for Bacterial Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Pertussis / Whooping Cough Vaccines, Other Vaccine Types, Tetanus Vaccines, Diphtheria Vaccines, Pneumococcal Vaccines, Meningococcal Vaccines, Typhoid Vaccines, Tuberculosis Vaccines, Cholera Vaccines and Shigellosis Vaccines for the Years 2015, 2025 & 2030
    • TABLE 155: Italy Recent Past, Current & Future Analysis for Bacterial Vaccines by Patient Age Group - Pediatric Vaccines, Adolescent Vaccines, Adult Vaccines and Geriatric Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Italy Historic Review for Bacterial Vaccines by Patient Age Group - Pediatric Vaccines, Adolescent Vaccines, Adult Vaccines and Geriatric Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 157: Italy 15-Year Perspective for Bacterial Vaccines by Patient Age Group - Percentage Breakdown of Value Sales for Pediatric Vaccines, Adolescent Vaccines, Adult Vaccines and Geriatric Vaccines for the Years 2015, 2025 & 2030
    • TABLE 158: Italy Recent Past, Current & Future Analysis for Bacterial Vaccines by Administration Route - Intramuscular, Intravenous, Subcutaneous and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Italy Historic Review for Bacterial Vaccines by Administration Route - Intramuscular, Intravenous, Subcutaneous and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 160: Italy 15-Year Perspective for Bacterial Vaccines by Administration Route - Percentage Breakdown of Value Sales for Intramuscular, Intravenous, Subcutaneous and Other Administration Routes for the Years 2015, 2025 & 2030
    • TABLE 161: Italy Recent Past, Current & Future Analysis for Bacterial Vaccines by Distribution Channel - Public and Private - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Italy Historic Review for Bacterial Vaccines by Distribution Channel - Public and Private Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 163: Italy 15-Year Perspective for Bacterial Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Public and Private for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Bacterial Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 164: UK Recent Past, Current & Future Analysis for Bacterial Vaccines by Vaccine Type - Pertussis / Whooping Cough Vaccines, Other Vaccine Types, Tetanus Vaccines, Diphtheria Vaccines, Pneumococcal Vaccines, Meningococcal Vaccines, Typhoid Vaccines, Tuberculosis Vaccines, Cholera Vaccines and Shigellosis Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 165: UK Historic Review for Bacterial Vaccines by Vaccine Type - Pertussis / Whooping Cough Vaccines, Other Vaccine Types, Tetanus Vaccines, Diphtheria Vaccines, Pneumococcal Vaccines, Meningococcal Vaccines, Typhoid Vaccines, Tuberculosis Vaccines, Cholera Vaccines and Shigellosis Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 166: UK 15-Year Perspective for Bacterial Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Pertussis / Whooping Cough Vaccines, Other Vaccine Types, Tetanus Vaccines, Diphtheria Vaccines, Pneumococcal Vaccines, Meningococcal Vaccines, Typhoid Vaccines, Tuberculosis Vaccines, Cholera Vaccines and Shigellosis Vaccines for the Years 2015, 2025 & 2030
    • TABLE 167: UK Recent Past, Current & Future Analysis for Bacterial Vaccines by Patient Age Group - Pediatric Vaccines, Adolescent Vaccines, Adult Vaccines and Geriatric Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 168: UK Historic Review for Bacterial Vaccines by Patient Age Group - Pediatric Vaccines, Adolescent Vaccines, Adult Vaccines and Geriatric Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 169: UK 15-Year Perspective for Bacterial Vaccines by Patient Age Group - Percentage Breakdown of Value Sales for Pediatric Vaccines, Adolescent Vaccines, Adult Vaccines and Geriatric Vaccines for the Years 2015, 2025 & 2030
    • TABLE 170: UK Recent Past, Current & Future Analysis for Bacterial Vaccines by Administration Route - Intramuscular, Intravenous, Subcutaneous and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 171: UK Historic Review for Bacterial Vaccines by Administration Route - Intramuscular, Intravenous, Subcutaneous and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 172: UK 15-Year Perspective for Bacterial Vaccines by Administration Route - Percentage Breakdown of Value Sales for Intramuscular, Intravenous, Subcutaneous and Other Administration Routes for the Years 2015, 2025 & 2030
    • TABLE 173: UK Recent Past, Current & Future Analysis for Bacterial Vaccines by Distribution Channel - Public and Private - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 174: UK Historic Review for Bacterial Vaccines by Distribution Channel - Public and Private Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 175: UK 15-Year Perspective for Bacterial Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Public and Private for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 176: Spain Recent Past, Current & Future Analysis for Bacterial Vaccines by Vaccine Type - Pertussis / Whooping Cough Vaccines, Other Vaccine Types, Tetanus Vaccines, Diphtheria Vaccines, Pneumococcal Vaccines, Meningococcal Vaccines, Typhoid Vaccines, Tuberculosis Vaccines, Cholera Vaccines and Shigellosis Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Spain Historic Review for Bacterial Vaccines by Vaccine Type - Pertussis / Whooping Cough Vaccines, Other Vaccine Types, Tetanus Vaccines, Diphtheria Vaccines, Pneumococcal Vaccines, Meningococcal Vaccines, Typhoid Vaccines, Tuberculosis Vaccines, Cholera Vaccines and Shigellosis Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 178: Spain 15-Year Perspective for Bacterial Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Pertussis / Whooping Cough Vaccines, Other Vaccine Types, Tetanus Vaccines, Diphtheria Vaccines, Pneumococcal Vaccines, Meningococcal Vaccines, Typhoid Vaccines, Tuberculosis Vaccines, Cholera Vaccines and Shigellosis Vaccines for the Years 2015, 2025 & 2030
    • TABLE 179: Spain Recent Past, Current & Future Analysis for Bacterial Vaccines by Patient Age Group - Pediatric Vaccines, Adolescent Vaccines, Adult Vaccines and Geriatric Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Spain Historic Review for Bacterial Vaccines by Patient Age Group - Pediatric Vaccines, Adolescent Vaccines, Adult Vaccines and Geriatric Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 181: Spain 15-Year Perspective for Bacterial Vaccines by Patient Age Group - Percentage Breakdown of Value Sales for Pediatric Vaccines, Adolescent Vaccines, Adult Vaccines and Geriatric Vaccines for the Years 2015, 2025 & 2030
    • TABLE 182: Spain Recent Past, Current & Future Analysis for Bacterial Vaccines by Administration Route - Intramuscular, Intravenous, Subcutaneous and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Spain Historic Review for Bacterial Vaccines by Administration Route - Intramuscular, Intravenous, Subcutaneous and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 184: Spain 15-Year Perspective for Bacterial Vaccines by Administration Route - Percentage Breakdown of Value Sales for Intramuscular, Intravenous, Subcutaneous and Other Administration Routes for the Years 2015, 2025 & 2030
    • TABLE 185: Spain Recent Past, Current & Future Analysis for Bacterial Vaccines by Distribution Channel - Public and Private - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Spain Historic Review for Bacterial Vaccines by Distribution Channel - Public and Private Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 187: Spain 15-Year Perspective for Bacterial Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Public and Private for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 188: Russia Recent Past, Current & Future Analysis for Bacterial Vaccines by Vaccine Type - Pertussis / Whooping Cough Vaccines, Other Vaccine Types, Tetanus Vaccines, Diphtheria Vaccines, Pneumococcal Vaccines, Meningococcal Vaccines, Typhoid Vaccines, Tuberculosis Vaccines, Cholera Vaccines and Shigellosis Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Russia Historic Review for Bacterial Vaccines by Vaccine Type - Pertussis / Whooping Cough Vaccines, Other Vaccine Types, Tetanus Vaccines, Diphtheria Vaccines, Pneumococcal Vaccines, Meningococcal Vaccines, Typhoid Vaccines, Tuberculosis Vaccines, Cholera Vaccines and Shigellosis Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 190: Russia 15-Year Perspective for Bacterial Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Pertussis / Whooping Cough Vaccines, Other Vaccine Types, Tetanus Vaccines, Diphtheria Vaccines, Pneumococcal Vaccines, Meningococcal Vaccines, Typhoid Vaccines, Tuberculosis Vaccines, Cholera Vaccines and Shigellosis Vaccines for the Years 2015, 2025 & 2030
    • TABLE 191: Russia Recent Past, Current & Future Analysis for Bacterial Vaccines by Patient Age Group - Pediatric Vaccines, Adolescent Vaccines, Adult Vaccines and Geriatric Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Russia Historic Review for Bacterial Vaccines by Patient Age Group - Pediatric Vaccines, Adolescent Vaccines, Adult Vaccines and Geriatric Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 193: Russia 15-Year Perspective for Bacterial Vaccines by Patient Age Group - Percentage Breakdown of Value Sales for Pediatric Vaccines, Adolescent Vaccines, Adult Vaccines and Geriatric Vaccines for the Years 2015, 2025 & 2030
    • TABLE 194: Russia Recent Past, Current & Future Analysis for Bacterial Vaccines by Administration Route - Intramuscular, Intravenous, Subcutaneous and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Russia Historic Review for Bacterial Vaccines by Administration Route - Intramuscular, Intravenous, Subcutaneous and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 196: Russia 15-Year Perspective for Bacterial Vaccines by Administration Route - Percentage Breakdown of Value Sales for Intramuscular, Intravenous, Subcutaneous and Other Administration Routes for the Years 2015, 2025 & 2030
    • TABLE 197: Russia Recent Past, Current & Future Analysis for Bacterial Vaccines by Distribution Channel - Public and Private - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Russia Historic Review for Bacterial Vaccines by Distribution Channel - Public and Private Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 199: Russia 15-Year Perspective for Bacterial Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Public and Private for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 200: Rest of Europe Recent Past, Current & Future Analysis for Bacterial Vaccines by Vaccine Type - Pertussis / Whooping Cough Vaccines, Other Vaccine Types, Tetanus Vaccines, Diphtheria Vaccines, Pneumococcal Vaccines, Meningococcal Vaccines, Typhoid Vaccines, Tuberculosis Vaccines, Cholera Vaccines and Shigellosis Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Rest of Europe Historic Review for Bacterial Vaccines by Vaccine Type - Pertussis / Whooping Cough Vaccines, Other Vaccine Types, Tetanus Vaccines, Diphtheria Vaccines, Pneumococcal Vaccines, Meningococcal Vaccines, Typhoid Vaccines, Tuberculosis Vaccines, Cholera Vaccines and Shigellosis Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 202: Rest of Europe 15-Year Perspective for Bacterial Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Pertussis / Whooping Cough Vaccines, Other Vaccine Types, Tetanus Vaccines, Diphtheria Vaccines, Pneumococcal Vaccines, Meningococcal Vaccines, Typhoid Vaccines, Tuberculosis Vaccines, Cholera Vaccines and Shigellosis Vaccines for the Years 2015, 2025 & 2030
    • TABLE 203: Rest of Europe Recent Past, Current & Future Analysis for Bacterial Vaccines by Patient Age Group - Pediatric Vaccines, Adolescent Vaccines, Adult Vaccines and Geriatric Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Rest of Europe Historic Review for Bacterial Vaccines by Patient Age Group - Pediatric Vaccines, Adolescent Vaccines, Adult Vaccines and Geriatric Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 205: Rest of Europe 15-Year Perspective for Bacterial Vaccines by Patient Age Group - Percentage Breakdown of Value Sales for Pediatric Vaccines, Adolescent Vaccines, Adult Vaccines and Geriatric Vaccines for the Years 2015, 2025 & 2030
    • TABLE 206: Rest of Europe Recent Past, Current & Future Analysis for Bacterial Vaccines by Administration Route - Intramuscular, Intravenous, Subcutaneous and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Rest of Europe Historic Review for Bacterial Vaccines by Administration Route - Intramuscular, Intravenous, Subcutaneous and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 208: Rest of Europe 15-Year Perspective for Bacterial Vaccines by Administration Route - Percentage Breakdown of Value Sales for Intramuscular, Intravenous, Subcutaneous and Other Administration Routes for the Years 2015, 2025 & 2030
    • TABLE 209: Rest of Europe Recent Past, Current & Future Analysis for Bacterial Vaccines by Distribution Channel - Public and Private - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Rest of Europe Historic Review for Bacterial Vaccines by Distribution Channel - Public and Private Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 211: Rest of Europe 15-Year Perspective for Bacterial Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Public and Private for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Bacterial Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 212: Asia-Pacific Recent Past, Current & Future Analysis for Bacterial Vaccines by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 213: Asia-Pacific Historic Review for Bacterial Vaccines by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 214: Asia-Pacific 15-Year Perspective for Bacterial Vaccines by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 215: Asia-Pacific Recent Past, Current & Future Analysis for Bacterial Vaccines by Vaccine Type - Pertussis / Whooping Cough Vaccines, Other Vaccine Types, Tetanus Vaccines, Diphtheria Vaccines, Pneumococcal Vaccines, Meningococcal Vaccines, Typhoid Vaccines, Tuberculosis Vaccines, Cholera Vaccines and Shigellosis Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 216: Asia-Pacific Historic Review for Bacterial Vaccines by Vaccine Type - Pertussis / Whooping Cough Vaccines, Other Vaccine Types, Tetanus Vaccines, Diphtheria Vaccines, Pneumococcal Vaccines, Meningococcal Vaccines, Typhoid Vaccines, Tuberculosis Vaccines, Cholera Vaccines and Shigellosis Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 217: Asia-Pacific 15-Year Perspective for Bacterial Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Pertussis / Whooping Cough Vaccines, Other Vaccine Types, Tetanus Vaccines, Diphtheria Vaccines, Pneumococcal Vaccines, Meningococcal Vaccines, Typhoid Vaccines, Tuberculosis Vaccines, Cholera Vaccines and Shigellosis Vaccines for the Years 2015, 2025 & 2030
    • TABLE 218: Asia-Pacific Recent Past, Current & Future Analysis for Bacterial Vaccines by Patient Age Group - Pediatric Vaccines, Adolescent Vaccines, Adult Vaccines and Geriatric Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 219: Asia-Pacific Historic Review for Bacterial Vaccines by Patient Age Group - Pediatric Vaccines, Adolescent Vaccines, Adult Vaccines and Geriatric Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 220: Asia-Pacific 15-Year Perspective for Bacterial Vaccines by Patient Age Group - Percentage Breakdown of Value Sales for Pediatric Vaccines, Adolescent Vaccines, Adult Vaccines and Geriatric Vaccines for the Years 2015, 2025 & 2030
    • TABLE 221: Asia-Pacific Recent Past, Current & Future Analysis for Bacterial Vaccines by Administration Route - Intramuscular, Intravenous, Subcutaneous and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 222: Asia-Pacific Historic Review for Bacterial Vaccines by Administration Route - Intramuscular, Intravenous, Subcutaneous and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 223: Asia-Pacific 15-Year Perspective for Bacterial Vaccines by Administration Route - Percentage Breakdown of Value Sales for Intramuscular, Intravenous, Subcutaneous and Other Administration Routes for the Years 2015, 2025 & 2030
    • TABLE 224: Asia-Pacific Recent Past, Current & Future Analysis for Bacterial Vaccines by Distribution Channel - Public and Private - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 225: Asia-Pacific Historic Review for Bacterial Vaccines by Distribution Channel - Public and Private Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 226: Asia-Pacific 15-Year Perspective for Bacterial Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Public and Private for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • Bacterial Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 227: Australia Recent Past, Current & Future Analysis for Bacterial Vaccines by Vaccine Type - Pertussis / Whooping Cough Vaccines, Other Vaccine Types, Tetanus Vaccines, Diphtheria Vaccines, Pneumococcal Vaccines, Meningococcal Vaccines, Typhoid Vaccines, Tuberculosis Vaccines, Cholera Vaccines and Shigellosis Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 228: Australia Historic Review for Bacterial Vaccines by Vaccine Type - Pertussis / Whooping Cough Vaccines, Other Vaccine Types, Tetanus Vaccines, Diphtheria Vaccines, Pneumococcal Vaccines, Meningococcal Vaccines, Typhoid Vaccines, Tuberculosis Vaccines, Cholera Vaccines and Shigellosis Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 229: Australia 15-Year Perspective for Bacterial Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Pertussis / Whooping Cough Vaccines, Other Vaccine Types, Tetanus Vaccines, Diphtheria Vaccines, Pneumococcal Vaccines, Meningococcal Vaccines, Typhoid Vaccines, Tuberculosis Vaccines, Cholera Vaccines and Shigellosis Vaccines for the Years 2015, 2025 & 2030
    • TABLE 230: Australia Recent Past, Current & Future Analysis for Bacterial Vaccines by Patient Age Group - Pediatric Vaccines, Adolescent Vaccines, Adult Vaccines and Geriatric Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 231: Australia Historic Review for Bacterial Vaccines by Patient Age Group - Pediatric Vaccines, Adolescent Vaccines, Adult Vaccines and Geriatric Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 232: Australia 15-Year Perspective for Bacterial Vaccines by Patient Age Group - Percentage Breakdown of Value Sales for Pediatric Vaccines, Adolescent Vaccines, Adult Vaccines and Geriatric Vaccines for the Years 2015, 2025 & 2030
    • TABLE 233: Australia Recent Past, Current & Future Analysis for Bacterial Vaccines by Administration Route - Intramuscular, Intravenous, Subcutaneous and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 234: Australia Historic Review for Bacterial Vaccines by Administration Route - Intramuscular, Intravenous, Subcutaneous and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 235: Australia 15-Year Perspective for Bacterial Vaccines by Administration Route - Percentage Breakdown of Value Sales for Intramuscular, Intravenous, Subcutaneous and Other Administration Routes for the Years 2015, 2025 & 2030
    • TABLE 236: Australia Recent Past, Current & Future Analysis for Bacterial Vaccines by Distribution Channel - Public and Private - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 237: Australia Historic Review for Bacterial Vaccines by Distribution Channel - Public and Private Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 238: Australia 15-Year Perspective for Bacterial Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Public and Private for the Years 2015, 2025 & 2030
  • INDIA
    • Bacterial Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 239: India Recent Past, Current & Future Analysis for Bacterial Vaccines by Vaccine Type - Pertussis / Whooping Cough Vaccines, Other Vaccine Types, Tetanus Vaccines, Diphtheria Vaccines, Pneumococcal Vaccines, Meningococcal Vaccines, Typhoid Vaccines, Tuberculosis Vaccines, Cholera Vaccines and Shigellosis Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 240: India Historic Review for Bacterial Vaccines by Vaccine Type - Pertussis / Whooping Cough Vaccines, Other Vaccine Types, Tetanus Vaccines, Diphtheria Vaccines, Pneumococcal Vaccines, Meningococcal Vaccines, Typhoid Vaccines, Tuberculosis Vaccines, Cholera Vaccines and Shigellosis Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 241: India 15-Year Perspective for Bacterial Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Pertussis / Whooping Cough Vaccines, Other Vaccine Types, Tetanus Vaccines, Diphtheria Vaccines, Pneumococcal Vaccines, Meningococcal Vaccines, Typhoid Vaccines, Tuberculosis Vaccines, Cholera Vaccines and Shigellosis Vaccines for the Years 2015, 2025 & 2030
    • TABLE 242: India Recent Past, Current & Future Analysis for Bacterial Vaccines by Patient Age Group - Pediatric Vaccines, Adolescent Vaccines, Adult Vaccines and Geriatric Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 243: India Historic Review for Bacterial Vaccines by Patient Age Group - Pediatric Vaccines, Adolescent Vaccines, Adult Vaccines and Geriatric Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 244: India 15-Year Perspective for Bacterial Vaccines by Patient Age Group - Percentage Breakdown of Value Sales for Pediatric Vaccines, Adolescent Vaccines, Adult Vaccines and Geriatric Vaccines for the Years 2015, 2025 & 2030
    • TABLE 245: India Recent Past, Current & Future Analysis for Bacterial Vaccines by Administration Route - Intramuscular, Intravenous, Subcutaneous and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 246: India Historic Review for Bacterial Vaccines by Administration Route - Intramuscular, Intravenous, Subcutaneous and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 247: India 15-Year Perspective for Bacterial Vaccines by Administration Route - Percentage Breakdown of Value Sales for Intramuscular, Intravenous, Subcutaneous and Other Administration Routes for the Years 2015, 2025 & 2030
    • TABLE 248: India Recent Past, Current & Future Analysis for Bacterial Vaccines by Distribution Channel - Public and Private - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 249: India Historic Review for Bacterial Vaccines by Distribution Channel - Public and Private Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 250: India 15-Year Perspective for Bacterial Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Public and Private for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 251: South Korea Recent Past, Current & Future Analysis for Bacterial Vaccines by Vaccine Type - Pertussis / Whooping Cough Vaccines, Other Vaccine Types, Tetanus Vaccines, Diphtheria Vaccines, Pneumococcal Vaccines, Meningococcal Vaccines, Typhoid Vaccines, Tuberculosis Vaccines, Cholera Vaccines and Shigellosis Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 252: South Korea Historic Review for Bacterial Vaccines by Vaccine Type - Pertussis / Whooping Cough Vaccines, Other Vaccine Types, Tetanus Vaccines, Diphtheria Vaccines, Pneumococcal Vaccines, Meningococcal Vaccines, Typhoid Vaccines, Tuberculosis Vaccines, Cholera Vaccines and Shigellosis Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 253: South Korea 15-Year Perspective for Bacterial Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Pertussis / Whooping Cough Vaccines, Other Vaccine Types, Tetanus Vaccines, Diphtheria Vaccines, Pneumococcal Vaccines, Meningococcal Vaccines, Typhoid Vaccines, Tuberculosis Vaccines, Cholera Vaccines and Shigellosis Vaccines for the Years 2015, 2025 & 2030
    • TABLE 254: South Korea Recent Past, Current & Future Analysis for Bacterial Vaccines by Patient Age Group - Pediatric Vaccines, Adolescent Vaccines, Adult Vaccines and Geriatric Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 255: South Korea Historic Review for Bacterial Vaccines by Patient Age Group - Pediatric Vaccines, Adolescent Vaccines, Adult Vaccines and Geriatric Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 256: South Korea 15-Year Perspective for Bacterial Vaccines by Patient Age Group - Percentage Breakdown of Value Sales for Pediatric Vaccines, Adolescent Vaccines, Adult Vaccines and Geriatric Vaccines for the Years 2015, 2025 & 2030
    • TABLE 257: South Korea Recent Past, Current & Future Analysis for Bacterial Vaccines by Administration Route - Intramuscular, Intravenous, Subcutaneous and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 258: South Korea Historic Review for Bacterial Vaccines by Administration Route - Intramuscular, Intravenous, Subcutaneous and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 259: South Korea 15-Year Perspective for Bacterial Vaccines by Administration Route - Percentage Breakdown of Value Sales for Intramuscular, Intravenous, Subcutaneous and Other Administration Routes for the Years 2015, 2025 & 2030
    • TABLE 260: South Korea Recent Past, Current & Future Analysis for Bacterial Vaccines by Distribution Channel - Public and Private - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 261: South Korea Historic Review for Bacterial Vaccines by Distribution Channel - Public and Private Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 262: South Korea 15-Year Perspective for Bacterial Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Public and Private for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 263: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Bacterial Vaccines by Vaccine Type - Pertussis / Whooping Cough Vaccines, Other Vaccine Types, Tetanus Vaccines, Diphtheria Vaccines, Pneumococcal Vaccines, Meningococcal Vaccines, Typhoid Vaccines, Tuberculosis Vaccines, Cholera Vaccines and Shigellosis Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 264: Rest of Asia-Pacific Historic Review for Bacterial Vaccines by Vaccine Type - Pertussis / Whooping Cough Vaccines, Other Vaccine Types, Tetanus Vaccines, Diphtheria Vaccines, Pneumococcal Vaccines, Meningococcal Vaccines, Typhoid Vaccines, Tuberculosis Vaccines, Cholera Vaccines and Shigellosis Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 265: Rest of Asia-Pacific 15-Year Perspective for Bacterial Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Pertussis / Whooping Cough Vaccines, Other Vaccine Types, Tetanus Vaccines, Diphtheria Vaccines, Pneumococcal Vaccines, Meningococcal Vaccines, Typhoid Vaccines, Tuberculosis Vaccines, Cholera Vaccines and Shigellosis Vaccines for the Years 2015, 2025 & 2030
    • TABLE 266: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Bacterial Vaccines by Patient Age Group - Pediatric Vaccines, Adolescent Vaccines, Adult Vaccines and Geriatric Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 267: Rest of Asia-Pacific Historic Review for Bacterial Vaccines by Patient Age Group - Pediatric Vaccines, Adolescent Vaccines, Adult Vaccines and Geriatric Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 268: Rest of Asia-Pacific 15-Year Perspective for Bacterial Vaccines by Patient Age Group - Percentage Breakdown of Value Sales for Pediatric Vaccines, Adolescent Vaccines, Adult Vaccines and Geriatric Vaccines for the Years 2015, 2025 & 2030
    • TABLE 269: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Bacterial Vaccines by Administration Route - Intramuscular, Intravenous, Subcutaneous and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 270: Rest of Asia-Pacific Historic Review for Bacterial Vaccines by Administration Route - Intramuscular, Intravenous, Subcutaneous and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 271: Rest of Asia-Pacific 15-Year Perspective for Bacterial Vaccines by Administration Route - Percentage Breakdown of Value Sales for Intramuscular, Intravenous, Subcutaneous and Other Administration Routes for the Years 2015, 2025 & 2030
    • TABLE 272: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Bacterial Vaccines by Distribution Channel - Public and Private - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 273: Rest of Asia-Pacific Historic Review for Bacterial Vaccines by Distribution Channel - Public and Private Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 274: Rest of Asia-Pacific 15-Year Perspective for Bacterial Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Public and Private for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • Bacterial Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 275: Latin America Recent Past, Current & Future Analysis for Bacterial Vaccines by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 276: Latin America Historic Review for Bacterial Vaccines by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 277: Latin America 15-Year Perspective for Bacterial Vaccines by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 278: Latin America Recent Past, Current & Future Analysis for Bacterial Vaccines by Vaccine Type - Pertussis / Whooping Cough Vaccines, Other Vaccine Types, Tetanus Vaccines, Diphtheria Vaccines, Pneumococcal Vaccines, Meningococcal Vaccines, Typhoid Vaccines, Tuberculosis Vaccines, Cholera Vaccines and Shigellosis Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 279: Latin America Historic Review for Bacterial Vaccines by Vaccine Type - Pertussis / Whooping Cough Vaccines, Other Vaccine Types, Tetanus Vaccines, Diphtheria Vaccines, Pneumococcal Vaccines, Meningococcal Vaccines, Typhoid Vaccines, Tuberculosis Vaccines, Cholera Vaccines and Shigellosis Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 280: Latin America 15-Year Perspective for Bacterial Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Pertussis / Whooping Cough Vaccines, Other Vaccine Types, Tetanus Vaccines, Diphtheria Vaccines, Pneumococcal Vaccines, Meningococcal Vaccines, Typhoid Vaccines, Tuberculosis Vaccines, Cholera Vaccines and Shigellosis Vaccines for the Years 2015, 2025 & 2030
    • TABLE 281: Latin America Recent Past, Current & Future Analysis for Bacterial Vaccines by Patient Age Group - Pediatric Vaccines, Adolescent Vaccines, Adult Vaccines and Geriatric Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 282: Latin America Historic Review for Bacterial Vaccines by Patient Age Group - Pediatric Vaccines, Adolescent Vaccines, Adult Vaccines and Geriatric Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 283: Latin America 15-Year Perspective for Bacterial Vaccines by Patient Age Group - Percentage Breakdown of Value Sales for Pediatric Vaccines, Adolescent Vaccines, Adult Vaccines and Geriatric Vaccines for the Years 2015, 2025 & 2030
    • TABLE 284: Latin America Recent Past, Current & Future Analysis for Bacterial Vaccines by Administration Route - Intramuscular, Intravenous, Subcutaneous and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 285: Latin America Historic Review for Bacterial Vaccines by Administration Route - Intramuscular, Intravenous, Subcutaneous and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 286: Latin America 15-Year Perspective for Bacterial Vaccines by Administration Route - Percentage Breakdown of Value Sales for Intramuscular, Intravenous, Subcutaneous and Other Administration Routes for the Years 2015, 2025 & 2030
    • TABLE 287: Latin America Recent Past, Current & Future Analysis for Bacterial Vaccines by Distribution Channel - Public and Private - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 288: Latin America Historic Review for Bacterial Vaccines by Distribution Channel - Public and Private Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 289: Latin America 15-Year Perspective for Bacterial Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Public and Private for the Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 290: Argentina Recent Past, Current & Future Analysis for Bacterial Vaccines by Vaccine Type - Pertussis / Whooping Cough Vaccines, Other Vaccine Types, Tetanus Vaccines, Diphtheria Vaccines, Pneumococcal Vaccines, Meningococcal Vaccines, Typhoid Vaccines, Tuberculosis Vaccines, Cholera Vaccines and Shigellosis Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 291: Argentina Historic Review for Bacterial Vaccines by Vaccine Type - Pertussis / Whooping Cough Vaccines, Other Vaccine Types, Tetanus Vaccines, Diphtheria Vaccines, Pneumococcal Vaccines, Meningococcal Vaccines, Typhoid Vaccines, Tuberculosis Vaccines, Cholera Vaccines and Shigellosis Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 292: Argentina 15-Year Perspective for Bacterial Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Pertussis / Whooping Cough Vaccines, Other Vaccine Types, Tetanus Vaccines, Diphtheria Vaccines, Pneumococcal Vaccines, Meningococcal Vaccines, Typhoid Vaccines, Tuberculosis Vaccines, Cholera Vaccines and Shigellosis Vaccines for the Years 2015, 2025 & 2030
    • TABLE 293: Argentina Recent Past, Current & Future Analysis for Bacterial Vaccines by Patient Age Group - Pediatric Vaccines, Adolescent Vaccines, Adult Vaccines and Geriatric Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 294: Argentina Historic Review for Bacterial Vaccines by Patient Age Group - Pediatric Vaccines, Adolescent Vaccines, Adult Vaccines and Geriatric Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 295: Argentina 15-Year Perspective for Bacterial Vaccines by Patient Age Group - Percentage Breakdown of Value Sales for Pediatric Vaccines, Adolescent Vaccines, Adult Vaccines and Geriatric Vaccines for the Years 2015, 2025 & 2030
    • TABLE 296: Argentina Recent Past, Current & Future Analysis for Bacterial Vaccines by Administration Route - Intramuscular, Intravenous, Subcutaneous and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 297: Argentina Historic Review for Bacterial Vaccines by Administration Route - Intramuscular, Intravenous, Subcutaneous and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 298: Argentina 15-Year Perspective for Bacterial Vaccines by Administration Route - Percentage Breakdown of Value Sales for Intramuscular, Intravenous, Subcutaneous and Other Administration Routes for the Years 2015, 2025 & 2030
    • TABLE 299: Argentina Recent Past, Current & Future Analysis for Bacterial Vaccines by Distribution Channel - Public and Private - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 300: Argentina Historic Review for Bacterial Vaccines by Distribution Channel - Public and Private Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 301: Argentina 15-Year Perspective for Bacterial Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Public and Private for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 302: Brazil Recent Past, Current & Future Analysis for Bacterial Vaccines by Vaccine Type - Pertussis / Whooping Cough Vaccines, Other Vaccine Types, Tetanus Vaccines, Diphtheria Vaccines, Pneumococcal Vaccines, Meningococcal Vaccines, Typhoid Vaccines, Tuberculosis Vaccines, Cholera Vaccines and Shigellosis Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 303: Brazil Historic Review for Bacterial Vaccines by Vaccine Type - Pertussis / Whooping Cough Vaccines, Other Vaccine Types, Tetanus Vaccines, Diphtheria Vaccines, Pneumococcal Vaccines, Meningococcal Vaccines, Typhoid Vaccines, Tuberculosis Vaccines, Cholera Vaccines and Shigellosis Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 304: Brazil 15-Year Perspective for Bacterial Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Pertussis / Whooping Cough Vaccines, Other Vaccine Types, Tetanus Vaccines, Diphtheria Vaccines, Pneumococcal Vaccines, Meningococcal Vaccines, Typhoid Vaccines, Tuberculosis Vaccines, Cholera Vaccines and Shigellosis Vaccines for the Years 2015, 2025 & 2030
    • TABLE 305: Brazil Recent Past, Current & Future Analysis for Bacterial Vaccines by Patient Age Group - Pediatric Vaccines, Adolescent Vaccines, Adult Vaccines and Geriatric Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 306: Brazil Historic Review for Bacterial Vaccines by Patient Age Group - Pediatric Vaccines, Adolescent Vaccines, Adult Vaccines and Geriatric Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 307: Brazil 15-Year Perspective for Bacterial Vaccines by Patient Age Group - Percentage Breakdown of Value Sales for Pediatric Vaccines, Adolescent Vaccines, Adult Vaccines and Geriatric Vaccines for the Years 2015, 2025 & 2030
    • TABLE 308: Brazil Recent Past, Current & Future Analysis for Bacterial Vaccines by Administration Route - Intramuscular, Intravenous, Subcutaneous and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 309: Brazil Historic Review for Bacterial Vaccines by Administration Route - Intramuscular, Intravenous, Subcutaneous and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 310: Brazil 15-Year Perspective for Bacterial Vaccines by Administration Route - Percentage Breakdown of Value Sales for Intramuscular, Intravenous, Subcutaneous and Other Administration Routes for the Years 2015, 2025 & 2030
    • TABLE 311: Brazil Recent Past, Current & Future Analysis for Bacterial Vaccines by Distribution Channel - Public and Private - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 312: Brazil Historic Review for Bacterial Vaccines by Distribution Channel - Public and Private Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 313: Brazil 15-Year Perspective for Bacterial Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Public and Private for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 314: Mexico Recent Past, Current & Future Analysis for Bacterial Vaccines by Vaccine Type - Pertussis / Whooping Cough Vaccines, Other Vaccine Types, Tetanus Vaccines, Diphtheria Vaccines, Pneumococcal Vaccines, Meningococcal Vaccines, Typhoid Vaccines, Tuberculosis Vaccines, Cholera Vaccines and Shigellosis Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 315: Mexico Historic Review for Bacterial Vaccines by Vaccine Type - Pertussis / Whooping Cough Vaccines, Other Vaccine Types, Tetanus Vaccines, Diphtheria Vaccines, Pneumococcal Vaccines, Meningococcal Vaccines, Typhoid Vaccines, Tuberculosis Vaccines, Cholera Vaccines and Shigellosis Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 316: Mexico 15-Year Perspective for Bacterial Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Pertussis / Whooping Cough Vaccines, Other Vaccine Types, Tetanus Vaccines, Diphtheria Vaccines, Pneumococcal Vaccines, Meningococcal Vaccines, Typhoid Vaccines, Tuberculosis Vaccines, Cholera Vaccines and Shigellosis Vaccines for the Years 2015, 2025 & 2030
    • TABLE 317: Mexico Recent Past, Current & Future Analysis for Bacterial Vaccines by Patient Age Group - Pediatric Vaccines, Adolescent Vaccines, Adult Vaccines and Geriatric Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 318: Mexico Historic Review for Bacterial Vaccines by Patient Age Group - Pediatric Vaccines, Adolescent Vaccines, Adult Vaccines and Geriatric Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 319: Mexico 15-Year Perspective for Bacterial Vaccines by Patient Age Group - Percentage Breakdown of Value Sales for Pediatric Vaccines, Adolescent Vaccines, Adult Vaccines and Geriatric Vaccines for the Years 2015, 2025 & 2030
    • TABLE 320: Mexico Recent Past, Current & Future Analysis for Bacterial Vaccines by Administration Route - Intramuscular, Intravenous, Subcutaneous and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 321: Mexico Historic Review for Bacterial Vaccines by Administration Route - Intramuscular, Intravenous, Subcutaneous and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 322: Mexico 15-Year Perspective for Bacterial Vaccines by Administration Route - Percentage Breakdown of Value Sales for Intramuscular, Intravenous, Subcutaneous and Other Administration Routes for the Years 2015, 2025 & 2030
    • TABLE 323: Mexico Recent Past, Current & Future Analysis for Bacterial Vaccines by Distribution Channel - Public and Private - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 324: Mexico Historic Review for Bacterial Vaccines by Distribution Channel - Public and Private Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 325: Mexico 15-Year Perspective for Bacterial Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Public and Private for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 326: Rest of Latin America Recent Past, Current & Future Analysis for Bacterial Vaccines by Vaccine Type - Pertussis / Whooping Cough Vaccines, Other Vaccine Types, Tetanus Vaccines, Diphtheria Vaccines, Pneumococcal Vaccines, Meningococcal Vaccines, Typhoid Vaccines, Tuberculosis Vaccines, Cholera Vaccines and Shigellosis Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 327: Rest of Latin America Historic Review for Bacterial Vaccines by Vaccine Type - Pertussis / Whooping Cough Vaccines, Other Vaccine Types, Tetanus Vaccines, Diphtheria Vaccines, Pneumococcal Vaccines, Meningococcal Vaccines, Typhoid Vaccines, Tuberculosis Vaccines, Cholera Vaccines and Shigellosis Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 328: Rest of Latin America 15-Year Perspective for Bacterial Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Pertussis / Whooping Cough Vaccines, Other Vaccine Types, Tetanus Vaccines, Diphtheria Vaccines, Pneumococcal Vaccines, Meningococcal Vaccines, Typhoid Vaccines, Tuberculosis Vaccines, Cholera Vaccines and Shigellosis Vaccines for the Years 2015, 2025 & 2030
    • TABLE 329: Rest of Latin America Recent Past, Current & Future Analysis for Bacterial Vaccines by Patient Age Group - Pediatric Vaccines, Adolescent Vaccines, Adult Vaccines and Geriatric Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 330: Rest of Latin America Historic Review for Bacterial Vaccines by Patient Age Group - Pediatric Vaccines, Adolescent Vaccines, Adult Vaccines and Geriatric Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 331: Rest of Latin America 15-Year Perspective for Bacterial Vaccines by Patient Age Group - Percentage Breakdown of Value Sales for Pediatric Vaccines, Adolescent Vaccines, Adult Vaccines and Geriatric Vaccines for the Years 2015, 2025 & 2030
    • TABLE 332: Rest of Latin America Recent Past, Current & Future Analysis for Bacterial Vaccines by Administration Route - Intramuscular, Intravenous, Subcutaneous and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 333: Rest of Latin America Historic Review for Bacterial Vaccines by Administration Route - Intramuscular, Intravenous, Subcutaneous and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 334: Rest of Latin America 15-Year Perspective for Bacterial Vaccines by Administration Route - Percentage Breakdown of Value Sales for Intramuscular, Intravenous, Subcutaneous and Other Administration Routes for the Years 2015, 2025 & 2030
    • TABLE 335: Rest of Latin America Recent Past, Current & Future Analysis for Bacterial Vaccines by Distribution Channel - Public and Private - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 336: Rest of Latin America Historic Review for Bacterial Vaccines by Distribution Channel - Public and Private Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 337: Rest of Latin America 15-Year Perspective for Bacterial Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Public and Private for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • Bacterial Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 338: Middle East Recent Past, Current & Future Analysis for Bacterial Vaccines by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 339: Middle East Historic Review for Bacterial Vaccines by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 340: Middle East 15-Year Perspective for Bacterial Vaccines by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 341: Middle East Recent Past, Current & Future Analysis for Bacterial Vaccines by Vaccine Type - Pertussis / Whooping Cough Vaccines, Other Vaccine Types, Tetanus Vaccines, Diphtheria Vaccines, Pneumococcal Vaccines, Meningococcal Vaccines, Typhoid Vaccines, Tuberculosis Vaccines, Cholera Vaccines and Shigellosis Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 342: Middle East Historic Review for Bacterial Vaccines by Vaccine Type - Pertussis / Whooping Cough Vaccines, Other Vaccine Types, Tetanus Vaccines, Diphtheria Vaccines, Pneumococcal Vaccines, Meningococcal Vaccines, Typhoid Vaccines, Tuberculosis Vaccines, Cholera Vaccines and Shigellosis Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 343: Middle East 15-Year Perspective for Bacterial Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Pertussis / Whooping Cough Vaccines, Other Vaccine Types, Tetanus Vaccines, Diphtheria Vaccines, Pneumococcal Vaccines, Meningococcal Vaccines, Typhoid Vaccines, Tuberculosis Vaccines, Cholera Vaccines and Shigellosis Vaccines for the Years 2015, 2025 & 2030
    • TABLE 344: Middle East Recent Past, Current & Future Analysis for Bacterial Vaccines by Patient Age Group - Pediatric Vaccines, Adolescent Vaccines, Adult Vaccines and Geriatric Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 345: Middle East Historic Review for Bacterial Vaccines by Patient Age Group - Pediatric Vaccines, Adolescent Vaccines, Adult Vaccines and Geriatric Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 346: Middle East 15-Year Perspective for Bacterial Vaccines by Patient Age Group - Percentage Breakdown of Value Sales for Pediatric Vaccines, Adolescent Vaccines, Adult Vaccines and Geriatric Vaccines for the Years 2015, 2025 & 2030
    • TABLE 347: Middle East Recent Past, Current & Future Analysis for Bacterial Vaccines by Administration Route - Intramuscular, Intravenous, Subcutaneous and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 348: Middle East Historic Review for Bacterial Vaccines by Administration Route - Intramuscular, Intravenous, Subcutaneous and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 349: Middle East 15-Year Perspective for Bacterial Vaccines by Administration Route - Percentage Breakdown of Value Sales for Intramuscular, Intravenous, Subcutaneous and Other Administration Routes for the Years 2015, 2025 & 2030
    • TABLE 350: Middle East Recent Past, Current & Future Analysis for Bacterial Vaccines by Distribution Channel - Public and Private - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 351: Middle East Historic Review for Bacterial Vaccines by Distribution Channel - Public and Private Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 352: Middle East 15-Year Perspective for Bacterial Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Public and Private for the Years 2015, 2025 & 2030
  • IRAN
    • TABLE 353: Iran Recent Past, Current & Future Analysis for Bacterial Vaccines by Vaccine Type - Pertussis / Whooping Cough Vaccines, Other Vaccine Types, Tetanus Vaccines, Diphtheria Vaccines, Pneumococcal Vaccines, Meningococcal Vaccines, Typhoid Vaccines, Tuberculosis Vaccines, Cholera Vaccines and Shigellosis Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 354: Iran Historic Review for Bacterial Vaccines by Vaccine Type - Pertussis / Whooping Cough Vaccines, Other Vaccine Types, Tetanus Vaccines, Diphtheria Vaccines, Pneumococcal Vaccines, Meningococcal Vaccines, Typhoid Vaccines, Tuberculosis Vaccines, Cholera Vaccines and Shigellosis Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 355: Iran 15-Year Perspective for Bacterial Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Pertussis / Whooping Cough Vaccines, Other Vaccine Types, Tetanus Vaccines, Diphtheria Vaccines, Pneumococcal Vaccines, Meningococcal Vaccines, Typhoid Vaccines, Tuberculosis Vaccines, Cholera Vaccines and Shigellosis Vaccines for the Years 2015, 2025 & 2030
    • TABLE 356: Iran Recent Past, Current & Future Analysis for Bacterial Vaccines by Patient Age Group - Pediatric Vaccines, Adolescent Vaccines, Adult Vaccines and Geriatric Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 357: Iran Historic Review for Bacterial Vaccines by Patient Age Group - Pediatric Vaccines, Adolescent Vaccines, Adult Vaccines and Geriatric Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 358: Iran 15-Year Perspective for Bacterial Vaccines by Patient Age Group - Percentage Breakdown of Value Sales for Pediatric Vaccines, Adolescent Vaccines, Adult Vaccines and Geriatric Vaccines for the Years 2015, 2025 & 2030
    • TABLE 359: Iran Recent Past, Current & Future Analysis for Bacterial Vaccines by Administration Route - Intramuscular, Intravenous, Subcutaneous and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 360: Iran Historic Review for Bacterial Vaccines by Administration Route - Intramuscular, Intravenous, Subcutaneous and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 361: Iran 15-Year Perspective for Bacterial Vaccines by Administration Route - Percentage Breakdown of Value Sales for Intramuscular, Intravenous, Subcutaneous and Other Administration Routes for the Years 2015, 2025 & 2030
    • TABLE 362: Iran Recent Past, Current & Future Analysis for Bacterial Vaccines by Distribution Channel - Public and Private - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 363: Iran Historic Review for Bacterial Vaccines by Distribution Channel - Public and Private Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 364: Iran 15-Year Perspective for Bacterial Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Public and Private for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 365: Israel Recent Past, Current & Future Analysis for Bacterial Vaccines by Vaccine Type - Pertussis / Whooping Cough Vaccines, Other Vaccine Types, Tetanus Vaccines, Diphtheria Vaccines, Pneumococcal Vaccines, Meningococcal Vaccines, Typhoid Vaccines, Tuberculosis Vaccines, Cholera Vaccines and Shigellosis Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 366: Israel Historic Review for Bacterial Vaccines by Vaccine Type - Pertussis / Whooping Cough Vaccines, Other Vaccine Types, Tetanus Vaccines, Diphtheria Vaccines, Pneumococcal Vaccines, Meningococcal Vaccines, Typhoid Vaccines, Tuberculosis Vaccines, Cholera Vaccines and Shigellosis Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 367: Israel 15-Year Perspective for Bacterial Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Pertussis / Whooping Cough Vaccines, Other Vaccine Types, Tetanus Vaccines, Diphtheria Vaccines, Pneumococcal Vaccines, Meningococcal Vaccines, Typhoid Vaccines, Tuberculosis Vaccines, Cholera Vaccines and Shigellosis Vaccines for the Years 2015, 2025 & 2030
    • TABLE 368: Israel Recent Past, Current & Future Analysis for Bacterial Vaccines by Patient Age Group - Pediatric Vaccines, Adolescent Vaccines, Adult Vaccines and Geriatric Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 369: Israel Historic Review for Bacterial Vaccines by Patient Age Group - Pediatric Vaccines, Adolescent Vaccines, Adult Vaccines and Geriatric Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 370: Israel 15-Year Perspective for Bacterial Vaccines by Patient Age Group - Percentage Breakdown of Value Sales for Pediatric Vaccines, Adolescent Vaccines, Adult Vaccines and Geriatric Vaccines for the Years 2015, 2025 & 2030
    • TABLE 371: Israel Recent Past, Current & Future Analysis for Bacterial Vaccines by Administration Route - Intramuscular, Intravenous, Subcutaneous and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 372: Israel Historic Review for Bacterial Vaccines by Administration Route - Intramuscular, Intravenous, Subcutaneous and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 373: Israel 15-Year Perspective for Bacterial Vaccines by Administration Route - Percentage Breakdown of Value Sales for Intramuscular, Intravenous, Subcutaneous and Other Administration Routes for the Years 2015, 2025 & 2030
    • TABLE 374: Israel Recent Past, Current & Future Analysis for Bacterial Vaccines by Distribution Channel - Public and Private - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 375: Israel Historic Review for Bacterial Vaccines by Distribution Channel - Public and Private Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 376: Israel 15-Year Perspective for Bacterial Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Public and Private for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 377: Saudi Arabia Recent Past, Current & Future Analysis for Bacterial Vaccines by Vaccine Type - Pertussis / Whooping Cough Vaccines, Other Vaccine Types, Tetanus Vaccines, Diphtheria Vaccines, Pneumococcal Vaccines, Meningococcal Vaccines, Typhoid Vaccines, Tuberculosis Vaccines, Cholera Vaccines and Shigellosis Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 378: Saudi Arabia Historic Review for Bacterial Vaccines by Vaccine Type - Pertussis / Whooping Cough Vaccines, Other Vaccine Types, Tetanus Vaccines, Diphtheria Vaccines, Pneumococcal Vaccines, Meningococcal Vaccines, Typhoid Vaccines, Tuberculosis Vaccines, Cholera Vaccines and Shigellosis Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 379: Saudi Arabia 15-Year Perspective for Bacterial Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Pertussis / Whooping Cough Vaccines, Other Vaccine Types, Tetanus Vaccines, Diphtheria Vaccines, Pneumococcal Vaccines, Meningococcal Vaccines, Typhoid Vaccines, Tuberculosis Vaccines, Cholera Vaccines and Shigellosis Vaccines for the Years 2015, 2025 & 2030
    • TABLE 380: Saudi Arabia Recent Past, Current & Future Analysis for Bacterial Vaccines by Patient Age Group - Pediatric Vaccines, Adolescent Vaccines, Adult Vaccines and Geriatric Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 381: Saudi Arabia Historic Review for Bacterial Vaccines by Patient Age Group - Pediatric Vaccines, Adolescent Vaccines, Adult Vaccines and Geriatric Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 382: Saudi Arabia 15-Year Perspective for Bacterial Vaccines by Patient Age Group - Percentage Breakdown of Value Sales for Pediatric Vaccines, Adolescent Vaccines, Adult Vaccines and Geriatric Vaccines for the Years 2015, 2025 & 2030
    • TABLE 383: Saudi Arabia Recent Past, Current & Future Analysis for Bacterial Vaccines by Administration Route - Intramuscular, Intravenous, Subcutaneous and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 384: Saudi Arabia Historic Review for Bacterial Vaccines by Administration Route - Intramuscular, Intravenous, Subcutaneous and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 385: Saudi Arabia 15-Year Perspective for Bacterial Vaccines by Administration Route - Percentage Breakdown of Value Sales for Intramuscular, Intravenous, Subcutaneous and Other Administration Routes for the Years 2015, 2025 & 2030
    • TABLE 386: Saudi Arabia Recent Past, Current & Future Analysis for Bacterial Vaccines by Distribution Channel - Public and Private - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 387: Saudi Arabia Historic Review for Bacterial Vaccines by Distribution Channel - Public and Private Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 388: Saudi Arabia 15-Year Perspective for Bacterial Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Public and Private for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 389: UAE Recent Past, Current & Future Analysis for Bacterial Vaccines by Vaccine Type - Pertussis / Whooping Cough Vaccines, Other Vaccine Types, Tetanus Vaccines, Diphtheria Vaccines, Pneumococcal Vaccines, Meningococcal Vaccines, Typhoid Vaccines, Tuberculosis Vaccines, Cholera Vaccines and Shigellosis Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 390: UAE Historic Review for Bacterial Vaccines by Vaccine Type - Pertussis / Whooping Cough Vaccines, Other Vaccine Types, Tetanus Vaccines, Diphtheria Vaccines, Pneumococcal Vaccines, Meningococcal Vaccines, Typhoid Vaccines, Tuberculosis Vaccines, Cholera Vaccines and Shigellosis Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 391: UAE 15-Year Perspective for Bacterial Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Pertussis / Whooping Cough Vaccines, Other Vaccine Types, Tetanus Vaccines, Diphtheria Vaccines, Pneumococcal Vaccines, Meningococcal Vaccines, Typhoid Vaccines, Tuberculosis Vaccines, Cholera Vaccines and Shigellosis Vaccines for the Years 2015, 2025 & 2030
    • TABLE 392: UAE Recent Past, Current & Future Analysis for Bacterial Vaccines by Patient Age Group - Pediatric Vaccines, Adolescent Vaccines, Adult Vaccines and Geriatric Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 393: UAE Historic Review for Bacterial Vaccines by Patient Age Group - Pediatric Vaccines, Adolescent Vaccines, Adult Vaccines and Geriatric Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 394: UAE 15-Year Perspective for Bacterial Vaccines by Patient Age Group - Percentage Breakdown of Value Sales for Pediatric Vaccines, Adolescent Vaccines, Adult Vaccines and Geriatric Vaccines for the Years 2015, 2025 & 2030
    • TABLE 395: UAE Recent Past, Current & Future Analysis for Bacterial Vaccines by Administration Route - Intramuscular, Intravenous, Subcutaneous and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 396: UAE Historic Review for Bacterial Vaccines by Administration Route - Intramuscular, Intravenous, Subcutaneous and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 397: UAE 15-Year Perspective for Bacterial Vaccines by Administration Route - Percentage Breakdown of Value Sales for Intramuscular, Intravenous, Subcutaneous and Other Administration Routes for the Years 2015, 2025 & 2030
    • TABLE 398: UAE Recent Past, Current & Future Analysis for Bacterial Vaccines by Distribution Channel - Public and Private - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 399: UAE Historic Review for Bacterial Vaccines by Distribution Channel - Public and Private Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 400: UAE 15-Year Perspective for Bacterial Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Public and Private for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 401: Rest of Middle East Recent Past, Current & Future Analysis for Bacterial Vaccines by Vaccine Type - Pertussis / Whooping Cough Vaccines, Other Vaccine Types, Tetanus Vaccines, Diphtheria Vaccines, Pneumococcal Vaccines, Meningococcal Vaccines, Typhoid Vaccines, Tuberculosis Vaccines, Cholera Vaccines and Shigellosis Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 402: Rest of Middle East Historic Review for Bacterial Vaccines by Vaccine Type - Pertussis / Whooping Cough Vaccines, Other Vaccine Types, Tetanus Vaccines, Diphtheria Vaccines, Pneumococcal Vaccines, Meningococcal Vaccines, Typhoid Vaccines, Tuberculosis Vaccines, Cholera Vaccines and Shigellosis Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 403: Rest of Middle East 15-Year Perspective for Bacterial Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Pertussis / Whooping Cough Vaccines, Other Vaccine Types, Tetanus Vaccines, Diphtheria Vaccines, Pneumococcal Vaccines, Meningococcal Vaccines, Typhoid Vaccines, Tuberculosis Vaccines, Cholera Vaccines and Shigellosis Vaccines for the Years 2015, 2025 & 2030
    • TABLE 404: Rest of Middle East Recent Past, Current & Future Analysis for Bacterial Vaccines by Patient Age Group - Pediatric Vaccines, Adolescent Vaccines, Adult Vaccines and Geriatric Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 405: Rest of Middle East Historic Review for Bacterial Vaccines by Patient Age Group - Pediatric Vaccines, Adolescent Vaccines, Adult Vaccines and Geriatric Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 406: Rest of Middle East 15-Year Perspective for Bacterial Vaccines by Patient Age Group - Percentage Breakdown of Value Sales for Pediatric Vaccines, Adolescent Vaccines, Adult Vaccines and Geriatric Vaccines for the Years 2015, 2025 & 2030
    • TABLE 407: Rest of Middle East Recent Past, Current & Future Analysis for Bacterial Vaccines by Administration Route - Intramuscular, Intravenous, Subcutaneous and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 408: Rest of Middle East Historic Review for Bacterial Vaccines by Administration Route - Intramuscular, Intravenous, Subcutaneous and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 409: Rest of Middle East 15-Year Perspective for Bacterial Vaccines by Administration Route - Percentage Breakdown of Value Sales for Intramuscular, Intravenous, Subcutaneous and Other Administration Routes for the Years 2015, 2025 & 2030
    • TABLE 410: Rest of Middle East Recent Past, Current & Future Analysis for Bacterial Vaccines by Distribution Channel - Public and Private - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 411: Rest of Middle East Historic Review for Bacterial Vaccines by Distribution Channel - Public and Private Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 412: Rest of Middle East 15-Year Perspective for Bacterial Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Public and Private for the Years 2015, 2025 & 2030
  • AFRICA
    • Bacterial Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 413: Africa Recent Past, Current & Future Analysis for Bacterial Vaccines by Vaccine Type - Pertussis / Whooping Cough Vaccines, Other Vaccine Types, Tetanus Vaccines, Diphtheria Vaccines, Pneumococcal Vaccines, Meningococcal Vaccines, Typhoid Vaccines, Tuberculosis Vaccines, Cholera Vaccines and Shigellosis Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 414: Africa Historic Review for Bacterial Vaccines by Vaccine Type - Pertussis / Whooping Cough Vaccines, Other Vaccine Types, Tetanus Vaccines, Diphtheria Vaccines, Pneumococcal Vaccines, Meningococcal Vaccines, Typhoid Vaccines, Tuberculosis Vaccines, Cholera Vaccines and Shigellosis Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 415: Africa 15-Year Perspective for Bacterial Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Pertussis / Whooping Cough Vaccines, Other Vaccine Types, Tetanus Vaccines, Diphtheria Vaccines, Pneumococcal Vaccines, Meningococcal Vaccines, Typhoid Vaccines, Tuberculosis Vaccines, Cholera Vaccines and Shigellosis Vaccines for the Years 2015, 2025 & 2030
    • TABLE 416: Africa Recent Past, Current & Future Analysis for Bacterial Vaccines by Patient Age Group - Pediatric Vaccines, Adolescent Vaccines, Adult Vaccines and Geriatric Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 417: Africa Historic Review for Bacterial Vaccines by Patient Age Group - Pediatric Vaccines, Adolescent Vaccines, Adult Vaccines and Geriatric Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 418: Africa 15-Year Perspective for Bacterial Vaccines by Patient Age Group - Percentage Breakdown of Value Sales for Pediatric Vaccines, Adolescent Vaccines, Adult Vaccines and Geriatric Vaccines for the Years 2015, 2025 & 2030
    • TABLE 419: Africa Recent Past, Current & Future Analysis for Bacterial Vaccines by Administration Route - Intramuscular, Intravenous, Subcutaneous and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 420: Africa Historic Review for Bacterial Vaccines by Administration Route - Intramuscular, Intravenous, Subcutaneous and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 421: Africa 15-Year Perspective for Bacterial Vaccines by Administration Route - Percentage Breakdown of Value Sales for Intramuscular, Intravenous, Subcutaneous and Other Administration Routes for the Years 2015, 2025 & 2030
    • TABLE 422: Africa Recent Past, Current & Future Analysis for Bacterial Vaccines by Distribution Channel - Public and Private - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 423: Africa Historic Review for Bacterial Vaccines by Distribution Channel - Public and Private Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 424: Africa 15-Year Perspective for Bacterial Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Public and Private for the Years 2015, 2025 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제